<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RAPAMUNE- sirolimus tablet, sugar coated </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Rapamune safely and effectively.<br>See full prescribing information for Rapamune.<br><br>RAPAMUNE (sirolimus) ORAL SOLUTION AND TABLETS<br>Initial U.S. Approval: 1999</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">IMMUNOSUPPRESSION</span>, EXCESS MORTALITY IN </span><span class="Bold"><span class="Italics">DE NOVO </span></span><span class="Bold">LIVER TRANSPLANTATION, AND BRONCHIAL ANASTOMOTIC DEHISCENCE</span>
</h1>
<h1 class="Warning">
<span class="Bold"><span class="Italics">See Full Prescribing Information for complete Boxed Warning</span></span>. </h1>
<ul>
<li>
<span class="Bold">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6">5.1</a></span></span><span class="Bold">). Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use Rapamune.</span>
</li>
<li>
<span class="Bold">The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in </span><span class="Bold"><span class="Italics">de novo </span></span><span class="Bold">liver or lung transplant patients, and therefore, such use is not recommended (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a>, <a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a></span></span><span class="Bold">).</span><ul>
<li>– <span class="Bold">Liver Transplantation – Excess mortality, graft loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">hepatic artery thrombosis</span> (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a></span></span><span class="Bold">).</span>
</li>
<li>– <span class="Bold">Lung Transplantation– Bronchial anastomotic dehiscence (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a></span></span><span class="Bold">).</span>
</li>
</ul>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="id_d2311ff7-429f-4d0c-8b8d-109dabc0e3a8"></a><table>
<col align="left" width="67.3%">
<col align="left" width="32.7%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><p class="Highlighta"><span class="Bold"><a href="#i4i_indications_id_56cc696d-f5e3-432b-b89c-4304c26c9881">Indications and Usage</a></span><br> </p></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li>Patients at high-immunologic risk (<span class="Italics"><a href="#i4i_section_id_1c44ae4e-b680-4479-aacc-a8ee7f9a56d1">1.1</a></span>) </li></ul></td>
<td align="left" valign="top"><p class="Highlighta">1/2007  </p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="Highlighta"><span class="Bold"><a href="#i4i_dosage_admin_id_5e54ea17-e064-481b-b328-d830e125bc89">Dosing and Administration</a></span> </p></td>
<td align="right" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><ul>
<li>Tablet administration (<span class="Italics"><a href="#i4i_dosage_admin_id_5e54ea17-e064-481b-b328-d830e125bc89">2</a></span>) <br>
</li>
<li>Therapeutic drug monitoring (<span class="Italics"><a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a></span>)<br>
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<span class="Italics"><a href="#i4i_section_id_2dd1f681-9297-43ad-825d-125c61cd3b3f">2.5</a></span>)</li>
</ul></td>
<td align="left" valign="top"><p class="Highlighta">10/2007<br>3/2008<br>3/2008<br> </p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="Highlighta"><span class="Bold"><a href="#i4i_warnings_precautions_id_c75bb73e-4037-4a23-be05-ca9c56c5e71e">Warnings and Precautions</a></span><br> </p></td>
<td align="right" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><ul>
<li>Increased Susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> and the Possible Development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (<span class="Italics"><a href="#i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6">5.1</a></span>) <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> (<span class="Italics"><a href="#i4i_section_id_b224f4fe-e243-4966-8d81-93c0286819f6">5.5</a></span>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> (<span class="Italics"><a href="#i4i_section_id_2318149a-ec06-482a-b5ee-745dcef84ad8">5.9</a></span>) <br>
</li>
<li>Fluid Accumulation and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing (<span class="Italics"><a href="#i4i_section_id_3356e104-dc30-4b87-8cec-7e4ff5077af0">5.6</a></span>) </li>
</ul></td>
<td align="left" valign="top"><p class="Highlighta">10/2007 <br>1/2007 <br>6/2007 <br>10/2007  </p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="Highlighta"><span class="Bold"><a href="#i4i_adverse_effects_id_7a92e608-7d7a-4ddd-8e82-fbb370dba16b">Adverse Reactions</a></span><br> </p></td>
<td align="left" valign="top"><p class="Highlighta"><br> </p></td>
</tr>
<tr>
<td align="left" valign="top"><ul><li>Conversion from Calcineurin Inhibitors to Rapamune in Maintenance Renal Transplant Population (<span class="Italics"><a href="#i4i_section_id_f5f8cfd9-646a-4928-a7ce-2bad0daaf4e8">6.4</a></span>) </li></ul></td>
<td align="left" valign="top"><p class="Highlighta">10/2007  </p></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><ul><li>Postmarketing Experience (<span class="Italics"><a href="#i4i_section_id_cb1b4701-d5a1-4996-9621-15fd59427022">6.6</a></span>) </li></ul></td>
<td align="left" valign="top"><p class="Highlighta">10/2007  </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">IMMUNOSUPPRESSION</span>, EXCESS MORTALITY IN </span><span class="Bold"><span class="Italics">DE NOVO </span></span><span class="Bold">LIVER TRANSPLANTATION, AND BRONCHIAL ANASTOMOTIC DEHISCENCE</span>
</h1>
<h1 class="Warning">
<span class="Bold"><span class="Italics">See Full Prescribing Information for complete Boxed Warning</span></span>. </h1>
<ul>
<li>
<span class="Bold">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6">5.1</a></span></span><span class="Bold">). Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use Rapamune.</span>
</li>
<li>
<span class="Bold">The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in </span><span class="Bold"><span class="Italics">de novo </span></span><span class="Bold">liver or lung transplant patients, and therefore, such use is not recommended (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a>, <a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a></span></span><span class="Bold">).</span><ul>
<li>– <span class="Bold">Liver Transplantation – Excess mortality, graft loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">hepatic artery thrombosis</span> (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a></span></span><span class="Bold">).</span>
</li>
<li>– <span class="Bold">Lung Transplantation– Bronchial anastomotic dehiscence (</span><span class="Bold"><span class="Italics"><a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a></span></span><span class="Bold">).</span>
</li>
</ul>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Rapamune is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants. </span> </p>
<ul>
<li> Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2-4 months after transplantation (<span class="Italics"><a href="#i4i_section_id_1c44ae4e-b680-4479-aacc-a8ee7f9a56d1">1.1</a></span>). </li>
<li> Patients at high-immunologic risk: Use in combination with cyclosporine and corticosteroids for the first 12 months following transplantation (<span class="Italics"><a href="#i4i_section_id_1c44ae4e-b680-4479-aacc-a8ee7f9a56d1">1.1</a></span>). Safety and efficacy of CsA withdrawal has not been established in high risk patients (<span class="Italics"><a href="#i4i_section_id_1c44ae4e-b680-4479-aacc-a8ee7f9a56d1">1.1</a></span>, <span class="Italics"><a href="#i4i_section_id_56970cd9-8cdd-44af-9158-70b75ba880e6">1.2</a></span>, <span class="Italics"><a href="#i4i_section_id_84a817be-e3ad-4544-88f6-3758a95edd14">14.3</a></span>). </li>
<li> Therapeutic drug monitoring is recommended for all patients (<span class="Italics"><a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a></span>, <span class="Italics"><a href="#i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f">5.14</a></span>). </li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul><li> Take once daily by mouth, consistently with or without food. Take the initial dose as soon as possible after transplantation and 4 hours after CsA (<span class="Italics"><a href="#i4i_dosage_admin_id_5e54ea17-e064-481b-b328-d830e125bc89">2</a></span>, <span class="Italics"><a href="#i4i_section_id_f7b1abd2-b040-4ca6-97ac-a9220528d63b">7.1</a></span>). Adjust the Rapamune maintenance dose to achieve sirolimus trough concentrations within the target-range (<span class="Italics"><a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a></span>). </li></ul>
<p class="Highlighta"><span class="Bold">Patients at low- to moderate-immunologic risk</span> </p>
<ul>
<li>Rapamune and Cyclosporine Combination Therapy: One loading dose of 6 mg on day 1, followed by daily maintenance doses of 2 mg (<span class="Italics"><a href="#i4i_section_id_9f366ab2-0574-4ab9-bf22-17ed85628dd4">2.1</a></span>). </li>
<li> Rapamune Following Cyclosporine Withdrawal: 2-4 months post-transplantation, withdraw CsA over 4-8 weeks (<span class="Italics"><a href="#i4i_section_id_57fa7449-144a-434d-b8f2-b49e927beb13">2.2</a></span>). </li>
</ul>
<p class="Highlighta"><span class="Bold">Patients at high-immunologic risk</span> </p>
<ul><li> Rapamune and Cyclosporine Combination Therapy (for the first 12 months post-transplantation): One loading dose of up to 15 mg on day 1, followed by daily maintenance doses of 5 mg (<span class="Italics"><a href="#i4i_section_id_57fa7449-144a-434d-b8f2-b49e927beb13">2.2</a></span>). </li></ul>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>
<span class="Bold">Rapamune Oral Solution:</span> 60 mg per 60 mL in amber glass bottle (<span class="Italics"><a href="#i4i_section_id_28ace6c7-cb2f-4efe-8027-b9fe2020bc3c">3.1</a></span>). </li>
<li>
<span class="Bold">Rapamune Tablets:</span> 1 mg, white; 2 mg, yellow-to-beige (<span class="Italics"><a href="#i4i_section_id_43691c8b-87a7-4128-bba7-ddd513c5398a">3.2</a></span>). </li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Rapamune (<span class="Italics"><a href="#i4i_contraindications_id_db7c9177-5b56-4d52-990e-f6c9a91d2642">4</a></span>).  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> (<span class="Italics"><a href="#i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7">5.4</a></span>) </li>
<li><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> (<span class="Italics"><a href="#i4i_section_id_b224f4fe-e243-4966-8d81-93c0286819f6">5.5</a></span>) </li>
<li>Fluid Accumulation and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing (<span class="Italics"><a href="#i4i_section_id_3356e104-dc30-4b87-8cec-7e4ff5077af0">5.6</a></span>) </li>
<li><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (<span class="Italics"><a href="#i4i_section_id_c3915daa-1a99-4bb3-a269-8520171ae66b">5.7</a></span>) </li>
<li>Renal Function (<span class="Italics"><a href="#i4i_section_id_c370c161-867e-4b26-9b49-e961de43442e">5.8</a></span>) </li>
<li><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> (<span class="Italics"><a href="#i4i_section_id_2318149a-ec06-482a-b5ee-745dcef84ad8">5.9</a></span>) </li>
<li><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> (<span class="Italics"><a href="#i4i_section_id_2ff38354-8cea-41b3-a7ea-edc42b92a96b">5.10</a></span>) </li>
<li>
<span class="Italics">De Novo</span> Use Without Cyclosporine (<span class="Italics"><a href="#i4i_section_id_6a9c361c-4e0d-4b76-8fa5-7c6b34fc2cd1">5.11</a></span>) </li>
<li>Increased Risk of Calcineurin Inhibitor-induced HUS/TTP/TMA (<span class="Italics"><a href="#i4i_section_id_8e82a9e2-0685-46a3-88b5-0ddcdc3681eb">5.12</a></span>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common (&gt; 30%) adverse reactions are: <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, creatinine increased, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (<span class="Italics"><a href="#i4i_adverse_effects_id_7a92e608-7d7a-4ddd-8e82-fbb370dba16b">6</a></span>).  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Wyeth Pharmaceuticals Inc. at 1-800-934-5556 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P‑gp inhibitors that decrease or increase sirolimus concentrations (<span class="Italics"><a href="#i4i_section_id_bd6972d4-0b36-4b71-aeed-17e65ef77bbe">7.4</a>, <a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a></span>). </li>
<li>Exercise caution when administering with drugs that are inhibitors/inducers of CYP3A4/P-gp (<span class="Italics"><a href="#i4i_section_id_bd6972d4-0b36-4b71-aeed-17e65ef77bbe">7.4</a>, <a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a></span>). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Use only if the potential benefit outweighs the potential risk to the embryo/fetus (<span class="Italics"><a href="#i4i_indications_id_56cc696d-f5e3-432b-b89c-4304c26c9881">8.1</a></span>). </li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Reduce maintenance dose in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<span class="Italics"><a href="#i4i_section_id_2dd1f681-9297-43ad-825d-125c61cd3b3f">2.5</a>, <a href="#i4i_section_id_2139620b-c685-4e9b-8f9f-b9cc5512570d">8.6</a>, <a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a></span>). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2008</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Prophylaxis of Organ Rejection in Renal Transplantation </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitations of Use </a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Patients at Low- to Moderate-Immunologic Risk </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients at High-Immunologic Risk </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Therapeutic Drug Monitoring </a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients with Low Body Weight </a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Instructions for Dilution and Administration of Rapamune Oral Solution </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h2><a href="#section-3.1" class="toc">3.1 Rapamune Oral Solution </a></h2>
<h2><a href="#section-3.2" class="toc">3.2 Rapamune Tablets </a></h2>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Increased Susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> and the Possible Development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Transplantation – Excess Mortality, Graft Loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">Hepatic Artery Thrombosis</span> (HAT) </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Lung Transplantation – Bronchial Anastomotic Dehiscence </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Fluid Accumulation and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Renal Function </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="Italics">De Novo</span> Use Without Cyclosporine </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Increased Risk of Calcineurin Inhibitor-Induced <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="313800" conceptname="Thrombotic microangiopathy">Thrombotic Microangiopathy</span> (HUS/TTP/TMA) </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Antimicrobial Prophylaxis </a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Assay for Sirolimus Therapeutic Drug Monitoring </a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Skin Cancer Events </a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience in Prophylaxis of Organ Rejection Following Renal Transplantation </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Rapamune Following Cyclosporine Withdrawal </a></h2>
<h2><a href="#section-6.3" class="toc">6.3 High-Immunologic Risk Patients </a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Conversion from Calcineurin Inhibitors to Rapamune in Maintenance Renal Transplant Population </a></h2>
<h2><a href="#section-6.5" class="toc">6.5 Pediatrics </a></h2>
<h2><a href="#section-6.6" class="toc">6.6 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Use with Cyclosporine </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Strong Inducers and Strong Inhibitors of CYP3A4 and P-gp </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Grapefruit Juice </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Inducers or Inhibitors of CYP3A4 and P-gp </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Vaccination </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Prophylaxis of Organ Rejection </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Cyclosporine Withdrawal Study </a></h2>
<h2><a href="#section-13.3" class="toc">14.3 High-Immunologic Risk Patients </a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Conversion from Calcineurin Inhibitors to Rapamune in Maintenance Renal Transplant Patients </a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Pediatrics </a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 Rapamune Oral Solution </a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Rapamune Tablets </a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Dosage </a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Skin Cancer Events </a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Pregnancy Risks </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_7227a690-a3c0-43a6-a1e5-108cf1450e05"></a><a name="section-1"></a><p></p>
<p class="First">BOX WARNING: <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">IMMUNOSUPPRESSION</span>, EXCESS MORTALITY IN <span class="Italics">DE NOVO</span> LIVER TRANSPLANTATION, AND BRONCHIAL ANASTOMOTIC DEHISCENCE </p>
<ul><li><span class="Bold"><a href="#i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span></a></span></li></ul>
<p><span class="Bold">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use Rapamune</span><span class="Sup">®</span><span class="Bold">. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see </span><span class="Bold"><span class="Italics">Warnings and Precautions (<span class="Italics"><a href="#i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6">5.1</a></span>)</span></span><span class="Bold">].</span></p>
<ul><li><span class="Bold"><a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">Liver Transplantation– Excess Mortality, Graft Loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">Hepatic Artery Thrombosis</span> (HAT)</a></span></li></ul>
<p><span class="Bold">The use of Rapamune in combination with tacrolimus was associated with excess mortality and graft loss in a study in <span class="Italics">de novo</span> liver transplant patients. Many of these patients had evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at or near the time of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span></p>
<p><span class="Bold">In this and another study in <span class="Italics">de novo</span> liver transplant patients, the use of Rapamune in combination with cyclosporine or tacrolimus was associated with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation and most led to graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [see </span><span class="Bold"><span class="Italics">Warnings and Precautions (<span class="Italics"><a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a></span>)</span></span><span class="Bold">].</span></p>
<ul><li><span class="Bold"><a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">Lung Transplantation– Bronchial Anastomotic Dehiscence</a></span></li></ul>
<p><span class="Bold">Cases of bronchial anastomotic dehiscence, most fatal, have been reported in <span class="Italics">de novo</span> lung transplant patients when Rapamune has been used as part of an immunosuppressive regimen [see </span><span class="Bold"><span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a>)</span></span><span class="Bold">].</span></p>
<ul><li>
<span class="Bold">The safety and efficacy of Rapamune (sirolimus) as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended [see </span><span class="Bold"><span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a>, <a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a>)</span></span><span class="Bold">].</span>
</li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_56cc696d-f5e3-432b-b89c-4304c26c9881"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c44ae4e-b680-4479-aacc-a8ee7f9a56d1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Prophylaxis of Organ Rejection in Renal Transplantation </h2>
<p class="First">Rapamune (sirolimus) is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. Therapeutic drug monitoring is recommended for all patients receiving Rapamune [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>), Warnings and Precautions (<a href="#i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f">5.14</a>)</span>]. </p>
<p><span class="Bold">In patients at low- to moderate-immunologic risk,</span> it is recommended that Rapamune be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_57fa7449-144a-434d-b8f2-b49e927beb13">2.2</a>)</span>]. </p>
<p><span class="Bold">In patients at high-immunologic risk</span> (defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level &gt; 80%]), it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_57fa7449-144a-434d-b8f2-b49e927beb13">2.2</a>), Clinical Studies (<a href="#i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363">14.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56970cd9-8cdd-44af-9158-70b75ba880e6"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Limitations of Use </h2>
<p class="First">Cyclosporine withdrawal has not been studied in patients with Banff Grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, those with serum creatinine &gt; 4.5 mg/dL, Black patients, patients of multi-organ transplants, secondary transplants, or those with high levels of panel-reactive antibodies [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363">14.2</a>)</span>]. </p>
<p><span class="Bold">In patients at high-immunologic risk,</span> the safety and efficacy of Rapamune used in combination with cyclosporine and corticosteroids has not been studied beyond one year; therefore after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_84a817be-e3ad-4544-88f6-3758a95edd14">14.3</a>)</span>]. </p>
<p><span class="Bold">In pediatric patients,</span> the safety and efficacy of Rapamune have not been established in patients &lt; 13 years old, or in pediatric (&lt; 18 years) renal transplant patients considered at high-immunologic risk [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_575660ad-6d6c-4d30-832f-f48d9feaa450">6.5</a>)</span>, <span class="Italics">Clinical Studies (<a href="#i4i_section_id_4f02c26f-b0c0-4ff6-911e-9a8d569ea51f">14.5</a>)</span>]. The safety and efficacy of <span class="Italics">de novo</span> use of Rapamune without cyclosporine have not been established in renal transplant patients [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6a9c361c-4e0d-4b76-8fa5-7c6b34fc2cd1">5.11</a>)</span>]. </p>
<p>The safety and efficacy of <span class="Bold">conversion from calcineurin inhibitors to Rapamune</span> in maintenance renal transplant patients have not been established [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363">14.2</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5e54ea17-e064-481b-b328-d830e125bc89"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Rapamune is to be administered orally once daily, consistently with or without food [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_1ad81e01-2cd7-4106-ae49-659cdae9e08b">2.4</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
<p>Tablets should not be crushed, chewed or split. Patients unable to take the tablets should be prescribed the solution and instructed in its use.</p>
<p>The initial dose of Rapamune should be administered as soon as possible after transplantation. It is recommended that Rapamune be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and or/cyclosporine capsules (MODIFIED) [see <span class="Italics">Drug Interactions (<a href="#i4i_section_id_bfffc254-2e96-4de1-8a9b-95d12c2e2cde">7.2</a>)</span>]. </p>
<p>Frequent Rapamune dose adjustments based on non-steady-state sirolimus concentrations can lead to overdosing or underdosing because sirolimus has a long half-life. Once Rapamune maintenance dose is adjusted, patients should continue on the new maintenance dose for at least 7 to 14 days before further dosage adjustment with concentration monitoring. In most patients, dose adjustments can be based on simple proportion: new Rapamune dose = current dose x (target concentration/current concentration). A loading dose should be considered in addition to a new maintenance dose when it is necessary to increase sirolimus trough concentrations: Rapamune loading dose = 3 x (new maintenance dose - current maintenance dose). The maximum Rapamune dose administered on any day should not exceed 40 mg. If an estimated daily dose exceeds 40 mg due to the addition of a loading dose, the loading dose should be administered over 2 days. Sirolimus trough concentrations should be monitored at least 3 to 4 days after a loading dose(s). </p>
<p>Two milligrams (2 mg) of Rapamune Oral Solution have been demonstrated to be clinically equivalent to 2 mg Rapamune Tablets; hence, are interchangeable on a mg-to-mg basis. However, it is not known if higher doses of Rapamune Oral Solution are clinically equivalent to higher doses of Rapamune Tablets on a mg‑to‑mg basis [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f366ab2-0574-4ab9-bf22-17ed85628dd4"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Patients at Low- to Moderate-Immunologic Risk </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b01511a-3b06-44f5-a521-728220b724f6"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">Rapamune and Cyclosporine Combination Therapy </span></h3>
<p class="First">For <span class="Italics">de novo</span> renal transplant patients, it is recommended that Rapamune Oral Solution and Tablets be used initially in a regimen with cyclosporine and corticosteroids. A loading dose of Rapamune equivalent to 3 times the maintenance dose should be given, i.e. a daily maintenance dose of 2 mg should be preceded with a loading dose of 6 mg. Therapeutic drug monitoring should be used to maintain sirolimus drug concentrations within the target-range [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24ff949a-3287-4a20-88b5-1d94c2834e94"></a><a name="section-2.1.2"></a><p></p>
<h3><span class="Bold">Rapamune Following Cyclosporine Withdrawal</span></h3>
<p class="First">At 2 to 4 months following transplantation, cyclosporine should be progressively discontinued over 4 to 8 weeks, and the Rapamune dose should be adjusted to obtain sirolimus whole blood trough concentrations within the target-range [see <span class="Italics">Dosage and Administration</span><span class="Italics"> (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>]. Because cyclosporine inhibits the metabolism and transport of sirolimus, sirolimus concentrations may decrease when cyclosporine is discontinued, unless the Rapamune dose is increased [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57fa7449-144a-434d-b8f2-b49e927beb13"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients at High-Immunologic Risk </h2>
<p class="First">In patients with high-immunologic risk, it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first 12 months following transplantation [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363">14.2</a>)</span>]. The safety and efficacy of this combination in high-immunologic risk patients has not been studied beyond the first 12 months. Therefore, after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient. </p>
<p>For patients receiving Rapamune with cyclosporine, Rapamune therapy should be initiated with a loading dose of up to 15 mg on day 1 post-transplantation. Beginning on day 2, an initial maintenance dose of 5 mg/day should be given. A trough level should be obtained between days 5 and 7, and the daily dose of Rapamune should thereafter be adjusted [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>]. </p>
<p>The starting dose of cyclosporine should be up to 7 mg/kg/day in divided doses and the dose should subsequently be adjusted to achieve target whole blood trough concentrations [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>]. Prednisone should be administered at a minimum of 5 mg/day. </p>
<p>Antibody induction therapy may be used. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Therapeutic Drug Monitoring </h2>
<p class="First">Monitoring of sirolimus trough concentrations is recommended for all patients, especially in those patients likely to have altered drug metabolism, in patients≥ 13 years who weigh less than 40 kg, in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>,when a change in the Rapamune dosage form is made, and during concurrent administration of strong CYP3A4 inducers and inhibitors [see <span class="Italics">Drug Interactions (<a href="#i4i_interactions_id_1c063075-59e7-474f-86f7-4d966060d10c">7</a>)</span>]. </p>
<p>Therapeutic drug monitoring should not be the sole basis for adjusting Rapamune therapy. Careful attention should be made to clinical signs/symptoms, tissue biopsy findings, and laboratory parameters. </p>
<p>When used in combination with cyclosporine, sirolimus trough concentrations should be maintained within the target-range [see <span class="Italics">Clinical Studies (<a href="#i4i_clinical_studies_id_d1c8db8b-91ac-4e5f-ae14-855176d29e51">14</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. Following cyclosporine withdrawal in transplant patients at low- to moderate-immunologic risk, the target sirolimus trough concentrations should be 16 to 24 ng/mL for the first year following transplantation. Thereafter, the target sirolimus concentrations should be 12 to 20 ng/mL. </p>
<p>The above recommended 24-hour trough concentration ranges for sirolimus are based on chromatographic methods. On average, chromatographic methods (HPLC UV or LC/MS/MS) yield results that are approximately 20% lower than the immunoassay for whole blood concentration determinations. Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. Because the measured sirolimus whole blood concentrations depend on the type of assay used, the concentrations obtained by these different methodologies are not interchangeable [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f">5.14</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. Adjustments to the targeted range should be made according to the assay utilized to determine sirolimus trough concentrations. A discussion of different assay methods is contained in Clinical Therapeutics, Volume 22, Supplement B, April 2000 [see <span class="Italics">References (<a href="#i4i_section_id_3a472451-f208-4299-ac8d-4ac34fc23158">15</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ad81e01-2cd7-4106-ae49-659cdae9e08b"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients with Low Body Weight </h2>
<p class="First">The initial dosage in patients ≥ 13 years who weigh less than 40 kg should be adjusted, based on body surface area, to 1 mg/m<span class="Sup">2</span>/day. The loading dose should be 3 mg/m<span class="Sup">2</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2dd1f681-9297-43ad-825d-125c61cd3b3f"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">It is recommended that the maintenance dose of Rapamune be reduced by approximately one third in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and by approximately one half in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. It is not necessary to modify the Rapamune loading dose [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_723c0e3d-3e11-4628-8e20-9e8a81f3cf3f"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Dosage adjustment is not needed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> [see <span class="Italics">Use in Specific Populations (<a href="#i4i_section_id_4bad18db-9b1a-4e1c-a278-7e3d52aacc13">8.7</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2bc958b-4da7-4c76-a8b3-afb4e3f13c1e"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Instructions for Dilution and Administration of Rapamune Oral Solution </h2>
<p class="First">The amber oral dose syringe should be used to withdraw the prescribed amount of Rapamune Oral Solution from the bottle. Empty the correct amount of Rapamune from the syringe into only a glass or plastic container holding at least two (2) ounces (1/4 cup, 60 mL) of water or orange juice. No other liquids, including grapefruit juice, should be used for dilution [see <span class="Italics">Drug Interactions (<a href="#i4i_section_id_0edaea58-d281-4a3e-a3fe-22c204ce1105">7.3</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. Stir vigorously and drink at once. Refill the container with an additional volume [minimum of four (4) ounces (1/2 cup, 120 mL)] of water or orange juice, stir vigorously, and drink at once. </p>
<p>Rapamune Oral Solution contains polysorbate 80, which is known to increase the rate of di‑(2‑ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of Rapamune Oral Solution. It is important that these recommendations be followed closely. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_68d882f9-afb7-4343-b084-2a69452fb84c"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28ace6c7-cb2f-4efe-8027-b9fe2020bc3c"></a><a name="section-3.1"></a><p></p>
<h2>3.1 Rapamune Oral Solution </h2>
<ul><li>60 mg per 60 mL in amber glass bottle. </li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43691c8b-87a7-4128-bba7-ddd513c5398a"></a><a name="section-3.2"></a><p></p>
<h2>3.2 Rapamune Tablets </h2>
<ul>
<li>1 mg, white, triangular-shaped tablets marked “RAPAMUNE 1 mg? on one side. </li>
<li>2 mg, yellow-to-beige triangular-shaped tablets marked “RAPAMUNE 2 mg? on one side. </li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_db7c9177-5b56-4d52-990e-f6c9a91d2642"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Rapamune is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Rapamune [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7">5.4</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_c75bb73e-4037-4a23-be05-ca9c56c5e71e"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Increased Susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> and the Possible Development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> </h2>
<p class="First">Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the possible development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, may result from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. The rates of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>/lymphoproliferative disease observed in Studies 1 and 2 were 0.7-3.2% (for Rapamune-treated patients) versus 0.6-0.8% (azathioprine and placebo control) [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_040fcef0-726c-4184-8408-6a5729e48ee9">6.1</a>)</span> and <span class="Italics">(<a href="#i4i_section_id_effb7181-d399-48f9-ac55-3ac628bf8a54">6.2</a>)</span>]. Oversuppression of the immune system can also increasesusceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> such as <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use Rapamune. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Transplantation – Excess Mortality, Graft Loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">Hepatic Artery Thrombosis</span> (HAT) </h2>
<p class="First">The use of Rapamune in combination with tacrolimus was associated with excess mortality and graft loss in a study in <span class="Italics">de novo</span> liver transplant patients (22% in combination versus 9% on tacrolimus alone). Many of these patients had evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at or near the time of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>In this and another study in <span class="Italics">de novo</span> liver transplant patients, the use of Rapamune in combination with cyclosporine or tacrolimus was associated with an increase in HAT (7% in combination versus 2% in the control arm); most cases of HAT occurred within 30 days post-transplantation, and most led to graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in liver transplant patients; therefore, such use is not recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Lung Transplantation – Bronchial Anastomotic Dehiscence </h2>
<p class="First">Cases of bronchial anastomotic dehiscence, most fatal, have been reported in <span class="Italics">de novo</span> lung transplant patients when Rapamune has been used as part of an immunosuppressive regimen. </p>
<p>The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in lung transplant patients; therefore, such use is not recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span>, have been associated with the administration of Rapamune [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_cb1b4701-d5a1-4996-9621-15fd59427022">6.6</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b224f4fe-e243-4966-8d81-93c0286819f6"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> </h2>
<p class="First">Rapamune has been associated with the development of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. The concomitant use of Rapamune with other drugs known to cause <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, such as ACE-inhibitors, may increase the risk of developing <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3356e104-dc30-4b87-8cec-7e4ff5077af0"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Fluid Accumulation and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing </h2>
<p class="First">There have been reports of impaired or delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing in patients receiving Rapamune, including <span class="product-label-link" type="condition" conceptid="4119772" conceptname="Lymphocele">lymphocele</span> and <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span> [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_040fcef0-726c-4184-8408-6a5729e48ee9">6.1</a>)</span>]. mTOR inhibitors such as sirolimus have been shown <span class="Italics">in vitro</span> to inhibit production of certain growth factors that may affect angiogenesis, fibroblast proliferation, and vascular permeability. <span class="product-label-link" type="condition" conceptid="4119772" conceptname="Lymphocele">Lymphocele</span>, a known surgical complication of renal transplantation, occurred significantly more often in a dose-related fashion in patients treated with Rapamune [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_040fcef0-726c-4184-8408-6a5729e48ee9">6.1</a>)</span>]. Appropriate measures should be considered to minimize such complications. Patients with a body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) greater than 30 kg/m<span class="Sup">2</span> may be at increased risk of abnormal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing based on data from the medical literature.</p>
<p>There have also been reports of fluid accumulation, including <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> and <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusions</span> (including hemodynamically significant <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusions</span> and tamponade requiring intervention in children and adults), in patients receiving Rapamune.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3915daa-1a99-4bb3-a269-8520171ae66b"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </h2>
<p class="First">Increased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides requiring treatment occurred more frequently in patients treated with Rapamune compared with azathioprine or placebo controls in Studies 1 and 2 [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_040fcef0-726c-4184-8408-6a5729e48ee9">6.1</a>)</span>]. There were increased incidences of <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (43-46%) and/or <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (45-57%) in patients receiving Rapamune compared with placebo controls (each 23%). The risk/benefit should be carefully considered in patients with established <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> before initiating an immunosuppressive regimen including Rapamune. </p>
<p>Any patient who is administered Rapamune should be monitored for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. If detected, interventions such as diet, exercise, and lipid-lowering agents should be initiated as outlined by the National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program guidelines. </p>
<p>In clinical trials, the concomitant administration of Rapamune and HMG-CoA reductase inhibitors and/or fibrates appeared to be well-tolerated. </p>
<p>During Rapamune therapy with cyclosporine, patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> and other adverse effects, as described in the respective labeling for these agents. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c370c161-867e-4b26-9b49-e961de43442e"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Renal Function </h2>
<p class="First">Renal function should be closely monitored during the co-administration of Rapamune with cyclosporine, because long-term administration of the combination has been associated with deterioration of renal function. Patients treated with cyclosporine and Rapamune were noted to have higher serum creatinine levels and lower glomerular filtration rates compared with patients treated with cyclosporine and placebo or azathioprine controls (Studies 1 and 2). The rate of decline in renal function in these studies was greater in patients receiving Rapamune and cyclosporine compared with control therapies. </p>
<p>Appropriate adjustment of the immunosuppressive regimen, including discontinuation of Rapamune and/or cyclosporine, should be considered in patients with elevated or increasing serum creatinine levels. In patients at low- to moderate-immunologic risk, continuation of combination therapy with cyclosporine beyond 4 months following transplantation should only be considered when the benefits outweigh the risks of this combination for the individual patients. Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. </p>
<p>In patients with delayed graft function, Rapamune may delay recovery of renal function. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2318149a-ec06-482a-b5ee-745dcef84ad8"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> </h2>
<p class="First">Periodic quantitative monitoring of urinary protein excretion is recommended. In a study evaluating conversion from calcineurin inhibitors (CNI) to Rapamune in maintenance renal transplant patients 6-120 months post-transplant, increased urinary protein excretion was commonly observed from 6 through 24 months after conversion to Rapamune compared with CNI continuation [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_9b21560b-a9b0-4fac-99a3-2fe516c6bc25">14.4</a>), Adverse Reactions (<a href="#i4i_section_id_f5f8cfd9-646a-4928-a7ce-2bad0daaf4e8">6.4</a>)</span>]. Patients with the greatest amount of urinary protein excretion prior to Rapamune conversion were those whose protein excretion increased the most after conversion.New onset <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> (<span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>) was also reported as a treatment-emergent adverse event in 2.2% of the Rapamune conversion group patients in comparison to 0.4% in the CNI continuation group of patients. Nephrotic range <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> (defined as urinary protein to creatinine ratio &gt; 3.5) was also reported in 9.2% in the Rapamune conversion group of patients in comparison to 3.7% in the CNI continuation group of patients. In some patients, reduction in the degree of urinary protein excretion was observed for individual patients following discontinuation of Rapamune. The safety and efficacy of conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ff38354-8cea-41b3-a7ea-edc42b92a96b"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> </h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span> <span class="product-label-link" type="condition" conceptid="4045260" conceptname="Bronchiolitis obliterans organizing pneumonia">organizing pneumonia</span> [BOOP], and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>), some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including Rapamune. In some cases, the <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> has resolved upon discontinuation or dose reduction of Rapamune. The risk may be increased as the trough sirolimus concentration increases [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_cb1b4701-d5a1-4996-9621-15fd59427022">6.6</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a9c361c-4e0d-4b76-8fa5-7c6b34fc2cd1"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="Italics">De Novo</span> Use Without Cyclosporine </h2>
<p class="First">The safety and efficacy of <span class="Italics">de novo</span> use of Rapamune without cyclosporine is not established in renal transplant patients. In a multicenter clinical study, <span class="Italics">de novo</span> renal transplant patients treated with Rapamune, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. A benefit, in terms of better renal function, was not apparent in the treatment arm with <span class="Italics">de novo</span> use of Rapamune without cyclosporine. These findings were also observed in a similar treatment group of another clinical trial. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e82a9e2-0685-46a3-88b5-0ddcdc3681eb"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Increased Risk of Calcineurin Inhibitor-Induced <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="313800" conceptname="Thrombotic microangiopathy">Thrombotic Microangiopathy</span> (HUS/TTP/TMA) </h2>
<p class="First">The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="313800" conceptname="Thrombotic microangiopathy">thrombotic microangiopathy</span> (HUS/TTP/TMA) [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_cb1b4701-d5a1-4996-9621-15fd59427022">6.6</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b8ae988a-f2ea-47d0-a794-f9798a0b7d35"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Antimicrobial Prophylaxis </h2>
<p class="First">Cases of <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> have been reported in patients not receiving antimicrobial prophylaxis. Therefore, antimicrobial prophylaxis for <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> should be administered for 1 year following transplantation. </p>
<p>Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Assay for Sirolimus Therapeutic Drug Monitoring </h2>
<p class="First">The label-recommended 24-hour trough concentration ranges for sirolimus are based on chromatographic methods. Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. These concentration values are not interchangeable [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a472451-f208-4299-ac8d-4ac34fc23158"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Skin Cancer Events </h2>
<p class="First">Patients on immunosuppressive therapy are at increased risk for skin cancer. Exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp </h2>
<p class="First">Co-administration of Rapamune with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) is not recommended [see <span class="Italics">Drug Interactions (<a href="#i4i_interactions_id_1c063075-59e7-474f-86f7-4d966060d10c">7</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7a92e608-7d7a-4ddd-8e82-fbb370dba16b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label. </p>
<ul>
<li>Increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and malignancy [see <span class="Italics">Boxed Warning</span>, <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_26bfb2b4-c65b-4111-ac31-4e0790e231b6">5.1</a>)</span>] </li>
<li>Excess mortality, graft loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">hepatic artery thrombosis</span> in liver transplant patients [see <span class="Italics">Boxed Warning</span>, <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_ce8e4f3d-c9ca-4f2a-b847-b5e76c5f0279">5.2</a>)</span>] </li>
<li>Bronchial anastomotic dehiscence in lung transplant patients [see <span class="Italics">Boxed Warning</span>, <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_aa3364e8-5766-41ca-84a7-e1a45dd97b24">5.3</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7">5.4</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7">5.4</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_b224f4fe-e243-4966-8d81-93c0286819f6">5.5</a>)</span>] </li>
<li>Fluid Accumulation and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_3356e104-dc30-4b87-8cec-7e4ff5077af0">5.6</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_c3915daa-1a99-4bb3-a269-8520171ae66b">5.7</a>)</span>] </li>
<li>Decline in renal function in long-term combination of cyclosporine with Rapamune [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_c370c161-867e-4b26-9b49-e961de43442e">5.8</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2318149a-ec06-482a-b5ee-745dcef84ad8">5.9</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2ff38354-8cea-41b3-a7ea-edc42b92a96b">5.10</a>)</span>] </li>
<li>Increased risk of calcineurin inhibitor-induced <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="313800" conceptname="Thrombotic microangiopathy">thrombotic microangiopathy</span> (HUS/TTP/TMA) [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_8e82a9e2-0685-46a3-88b5-0ddcdc3681eb">5.12</a>)</span>]. </li>
</ul>
<p>The most common (≥ 30%) adverse reactions observed with Rapamune in clinical studies are: <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, creatinine increased, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. </p>
<p>The following adverse reactions resulted in a rate of discontinuation of &gt; 5% in clinical trials: creatinine increased, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, and <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (TTP). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_040fcef0-726c-4184-8408-6a5729e48ee9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience in Prophylaxis of Organ Rejection Following Renal Transplantation </h2>
<p class="First">The safety and efficacy of Rapamune Oral Solution for the prevention of organ rejection following renal transplantation were assessed in two randomized, double-blind, multicenter, controlled trials [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_194bfdb6-af73-4213-ad64-5dcdfb1cf70e">14.1</a>)</span>]. The safety profiles in the two studies were similar. </p>
<p>The incidence of adverse reactions in the randomized, double-blind, multicenter, placebo-controlled trial (Study 2) in which 219 renal transplant patients received Rapamune Oral Solution 2 mg/day, 208 received Rapamune Oral Solution 5 mg/day, and 124 received placebo is presented in the <a href="#id_1323aaa6-74de-40eb-af98-c67437dc81c5">table</a> below. The study population had a mean age of 46 years (range 15 to 71 years), the distribution was 67% male, and the composition by race was: White (78%), Black (11%), Asian (3%), Hispanic (2%), and Other (5%). All patients were treated with cyclosporine and corticosteroids. Data (≥ 12 months post-transplant) presented in the following <a href="#id_1323aaa6-74de-40eb-af98-c67437dc81c5">table</a> show the adverse reactions that occurred in at least one of the Rapamune treatment groups with an incidence of ≥ 20%. </p>
<p>The safety profile of the tablet did not differ from that of the oral solution formulation [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_194bfdb6-af73-4213-ad64-5dcdfb1cf70e">14.1</a>)</span>]. </p>
<p>In general, adverse reactions related to the administration of Rapamune were dependent on dose/concentration. Although a daily maintenance dose of 5 mg, with a loading dose of 15 mg, was shown to be safe and effective, no efficacy advantage over the 2 mg dose could be established for renal transplant patients. Patients receiving 2 mg of Rapamune Oral Solution per day demonstrated an overall better safety profile than did patients receiving 5 mg of Rapamune Oral Solution per day. </p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice. </p>
<a name="id_1323aaa6-74de-40eb-af98-c67437dc81c5"></a><table width="422.000">
<caption><span>ADVERSE REACTIONS OCCURRING AT A FREQUENCY OF ≥ 20% IN AT LEAST ONE OF THE RAPAMUNE TREATMENT GROUPS IN A STUDY OF PROPHYLAXIS OF ORGAN REJECTION FOLLOWING RENAL TRANSPLANTATION (%) AT ≥ 12 MONTHS POST-TRANSPLANTATION (STUDY 2)<span class="Sup">a</span></span></caption>
<col align="left" width="30.6%">
<col align="left" width="22.5%">
<col align="left" width="22.5%">
<col align="left" width="24.4%">
<thead>
<tr class="First">
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" colspan="2" valign="top">–––Rapamune Oral Solution––– </td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top">2 mg/day </td>
<td align="center" valign="top">5 mg/day </td>
<td align="center" valign="top">Placebo </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Adverse Reaction </td>
<td class="Botrule" align="center" valign="top">(n = 218) </td>
<td class="Botrule" align="center" valign="top">(n = 208) </td>
<td class="Botrule" align="center" valign="top">(n = 124) </td>
</tr>
</thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> </p></td>
<td class="Toprule" align="center" valign="top">54</td>
<td class="Toprule" align="center" valign="top">58</td>
<td align="center" valign="top">48</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </p></td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">57</td>
<td align="center" valign="top">23</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p></td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">49</td>
<td align="center" valign="top">48</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> </p></td>
<td align="center" valign="top">43</td>
<td align="center" valign="top">46</td>
<td align="center" valign="top">23</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Creatinine increased </p></td>
<td align="center" valign="top">39</td>
<td align="center" valign="top">40</td>
<td align="center" valign="top">38</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td align="center" valign="top">36</td>
<td align="center" valign="top">38</td>
<td align="center" valign="top">31</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </p></td>
<td align="center" valign="top">29</td>
<td align="center" valign="top">36</td>
<td align="center" valign="top">30</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td align="center" valign="top">25</td>
<td align="center" valign="top">35</td>
<td align="center" valign="top">27</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td align="center" valign="top">34</td>
<td align="center" valign="top">34</td>
<td align="center" valign="top">31</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </p></td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">34</td>
<td align="center" valign="top">35</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> </p></td>
<td align="center" valign="top">26</td>
<td align="center" valign="top">33</td>
<td align="center" valign="top">26</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </p></td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">33</td>
<td align="center" valign="top">21</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td align="center" valign="top">25</td>
<td align="center" valign="top">31</td>
<td align="center" valign="top">29</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </p></td>
<td align="center" valign="top">25</td>
<td align="center" valign="top">31</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </p></td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td align="center" valign="top">33</td>
<td align="center" valign="top">29</td>
<td align="center" valign="top">25</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> </p></td>
<td align="center" valign="top">22</td>
<td align="center" valign="top">22</td>
<td align="center" valign="top">19</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </p></td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">20</td>
<td align="center" valign="top">6</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </p></td>
<td class="Botrule" align="center" valign="top">20</td>
<td class="Botrule" align="center" valign="top">18</td>
<td class="Botrule" align="center" valign="top">15</td>
</tr>
</tbody>
</table>
<p>The following adverse reactions were reported less frequently (≥ 3%, but &lt; 20%) </p>
<ul>
<li>
<span class="Bold"><span class="Italics">Body as a Whole</span></span> – <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span>, <span class="product-label-link" type="condition" conceptid="4119772" conceptname="Lymphocele">lymphocele</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, herpes simplex. </li>
<li>
<span class="Bold"><span class="Italics">Cardiovascular</span></span> – <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> (including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. </li>
<li>
<span class="Bold"><span class="Italics">Digestive System</span></span> – <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>. </li>
<li>
<span class="Bold"><span class="Italics">Hematologic and Lymphatic System</span></span> – <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS), <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. </li>
<li>
<span class="Bold"><span class="Italics">Metabolic/Nutritional</span></span> – Abnormal healing, increased lactic dehydrogenase (LDH), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. </li>
<li>
<span class="Bold"><span class="Italics">Musculoskeletal System</span></span> – <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Bone necrosis</span>. </li>
<li>
<span class="Bold"><span class="Italics">Respiratory System</span></span> – <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>. </li>
<li>
<span class="Bold"><span class="Italics">Skin</span></span> – Melanoma, squamous cell carcinoma, basal cell carcinoma. </li>
<li>
<span class="Bold"><span class="Italics">Urogenital System</span></span> – <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">Pyelonephritis</span>, decline in renal function (creatinine increased) in long-term combination of cyclosporine with Rapamune [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_c370c161-867e-4b26-9b49-e961de43442e">5.8</a>)</span>]. </li>
</ul>
<p>Less frequently (&lt; 3%) occurring adverse reactions included: <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>/post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span>, <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> (including <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, cytomegalovirus (CMV), and Epstein-Barr virus. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57e5cc24-90ab-48fc-8a06-c4866dc242a9"></a><a name="section-6.1.1"></a><p></p>
<h3>Increased Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and Triglycerides</h3>
<p class="First">The use of Rapamune in renal transplant patients was associated with increased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides that may require treatment. </p>
<p>In Studies 1 and 2, in <span class="Italics">de novo</span> renal transplant patients who began the study with fasting, total serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>&lt; 200 mg/dL or fasting, total serum triglycerides &lt; 200 mg/dL, there was an increased incidence of <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (fasting serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> &gt; 240 mg/dL) or <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (fasting serum triglycerides &gt; 500 mg/dL), respectively, in patients receiving both Rapamune 2 mg and Rapamune 5 mg compared with azathioprine and placebo controls. </p>
<p>Treatment of new-onset <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> with lipid-lowering agents was required in 42‑52% of patients enrolled in the Rapamune arms of Studies 1 and 2 compared with 16% of patients in the placebo arm and 22% of patients in the azathioprine arm. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f321f60-c59e-4a17-9e85-685cb6bb4af1"></a><a name="section-6.1.2"></a><p></p>
<h3>Abnormal Healing</h3>
<p class="First">Abnormal healing events following transplant surgery include fascial dehiscence, <span class="product-label-link" type="condition" conceptid="198464" conceptname="Incisional hernia">incisional hernia</span>, and anastomosis disruption (e.g., <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>, vascular, airway, ureteral, biliary). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6ee02c0-1f8a-4d3f-b33a-e23aba4b63d5"></a><a name="section-6.1.3"></a><p></p>
<h3>Malignancies</h3>
<p class="First">The <a href="#id_d8438ccd-fbe7-4b91-8801-d936f583bcb8">table</a> below summarizes the incidence of malignancies in the two controlled trials (Studies 1 and 2) for the prevention of acute rejection [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_194bfdb6-af73-4213-ad64-5dcdfb1cf70e">14.1</a>)</span>]. </p>
<p>At 24 months (Study 1) and 36 months (Study 2), there were no significant differences among treatment groups. </p>
<a name="id_d8438ccd-fbe7-4b91-8801-d936f583bcb8"></a><table width="425.000">
<caption><span>INCIDENCE (%) OF MALIGNANCIES IN STUDY 1 (24 MONTHS) AND STUDY 2 (36 MONTHS) POST-TRANSPLANT<span class="Sup">a,b</span></span></caption>
<col align="left" width="30.4%">
<col align="left" width="11.1%">
<col align="left" width="11.1%">
<col align="left" width="11.1%">
<col align="left" width="11.1%">
<col align="left" width="15.3%">
<col align="left" width="10.1%">
<thead>
<tr class="First">
<td class="Botrule Toprule" align="left" rowspan="2" valign="bottom"><p class="First">Malignancy </p></td>
<td class="Toprule" align="center" colspan="2" valign="top"> Rapamune<br>Oral Solution<br>2 mg/day</td>
<td class="Toprule" align="center" colspan="2" valign="top"> Rapamune<br>Oral Solution<br>5 mg/day</td>
<td class="Toprule" align="center" valign="bottom"> Azathioprine<br>2-3 mg/kg/day</td>
<td align="center" valign="bottom"> Placebo</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="bottom"> Study 1<br>(n = 284)</td>
<td class="Botrule" align="center" valign="bottom">Study 2<br>(n = 227)</td>
<td class="Botrule" align="center" valign="bottom"> Study 1<br>(n = 274)</td>
<td class="Botrule" align="center" valign="bottom"> Study 2<br>(n = 219)</td>
<td class="Botrule" align="center" valign="bottom"> Study 1<br>(n = 161)</td>
<td class="Botrule" align="center" valign="bottom"> Study 2<br>(n = 130)</td>
</tr>
</thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="7" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids. <br>b: Includes patients who prematurely discontinued treatment.<br>c: Patients may be counted in more than one category. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span>/<br>lymphoproliferative disease</span></p></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">0.7</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">1.8</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">1.1</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">3.2</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">0.6 </span></td>
<td align="center" valign="top"><span class="Bold">0.8</span></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Skin Carcinoma</span></p></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">     Any Squamous Cell<span class="Sup">c</span></p></td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">3.0</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">     Any Basal Cell<span class="Sup">c</span></p></td>
<td align="center" valign="top">0.7</td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">2.5</td>
<td align="center" valign="top">5.3</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">     Melanoma </p></td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">1.4</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.0</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">     Miscellaneous/Not Specified </p></td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Total</span></td>
<td align="center" valign="top"><span class="Bold">1.1</span></td>
<td align="center" valign="top"><span class="Bold">4.4</span></td>
<td align="center" valign="top"><span class="Bold">3.3</span></td>
<td align="center" valign="top"><span class="Bold">4.1</span></td>
<td align="center" valign="top"><span class="Bold">4.3</span></td>
<td align="center" valign="top"><span class="Bold">7.7</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><p class="First"><span class="Bold">Other Malignancy</span></p></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1.1</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">2.2</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1.5</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1.4</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">0.6</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">2.3</span></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_effb7181-d399-48f9-ac55-3ac628bf8a54"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Rapamune Following Cyclosporine Withdrawal </h2>
<p class="First">The incidence of adverse reactions was determined through 36 months in a randomized, multicenter, controlled trial (Study 3) in which 215 renal transplant patients received Rapamune as a maintenance regimen following cyclosporine withdrawal, and 215 patients received Rapamune with cyclosporine therapy [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363">14.2</a>)</span>]. All patients were treated with corticosteroids. The safety profile prior to randomization (start of cyclosporine withdrawal) was similar to that of the 2 mg Rapamune groups in Studies 1 and 2. </p>
<p>Following randomization (at 3 months), patients who had cyclosporine eliminated from their therapy experienced higher incidences of the following adverse reactions: <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> (including increased AST/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and increased ALT/SGPT), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and abnormal healing. Conversely, the incidence of the following adverse events was higher in patients who remained on cyclosporine than those who had cyclosporine withdrawn from therapy: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">cyclosporine toxicity</span>, increased creatinine, abnormal kidney function, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, and gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. Mean systolic and diastolic blood pressure improved significantly following cyclosporine withdrawal. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41ab82cc-0e3b-41ef-b3e3-73e6dac31c5f"></a><a name="section-6.2.1"></a><p></p>
<h3>Malignancies</h3>
<p class="First">The incidence of malignancies in Study 3 [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363">14.2</a>)</span>] is presented in the <a href="#id_1520aa38-c116-4913-87da-48dbf20a47d9">table</a> following. </p>
<p>In Study 3, the incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>/lymphoproliferative disease was similar in all treatment groups. The overall incidence of malignancy was higher in patients receiving Rapamune plus cyclosporine compared with patients who had cyclosporine withdrawn. Conclusions regarding these differences in the incidence of malignancy could not be made because Study 3 was not designed to consider malignancy risk factors or systematically screen subjects for malignancy. In addition, more patients in the Rapamune with cyclosporine group had a pretransplantation history of skin carcinoma. </p>
<a name="id_1520aa38-c116-4913-87da-48dbf20a47d9"></a><table width="430.000">
<caption><span>INCIDENCE (%) OF MALIGNANCIES IN STUDY 3 (CYCLOSPORINE WITHDRAWAL STUDY) AT 36 MONTHS POST-TRANSPLANT<span class="Sup">a,b</span></span></caption>
<col align="left" width="37.2%">
<col align="left" width="20.9%">
<col align="left" width="20.9%">
<col align="left" width="20.9%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom"><p class="First">Malignancy </p></td>
<td class="Botrule" align="center" valign="bottom">Nonrandomized<br>(n = 95)</td>
<td class="Botrule" align="center" valign="bottom">Rapamune with Cyclosporine<br>Therapy<br>(n = 215)</td>
<td class="Botrule" align="center" valign="bottom">Rapamune Following Cyclosporine Withdrawal<br>(n = 215)</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids.<br>b: Includes patients who prematurely discontinued treatment. <br>c: Patients may be counted in more than one category. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span>/<br>lymphoproliferative disease</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">1.1</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">1.4</span></td>
<td align="center" valign="top"><span class="Bold">0.5</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Skin Carcinoma</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Any Squamous Cell<span class="Sup">c</span>
</td>
<td align="center" valign="top">3.2</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">2.3</td>
</tr>
<tr>
<td align="left" valign="top">     Any Basal Cell<span class="Sup">c</span>
</td>
<td align="center" valign="top">3.2</td>
<td align="center" valign="top">6.5</td>
<td align="center" valign="top">2.3</td>
</tr>
<tr>
<td align="left" valign="top">     Melanoma</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">0.5</td>
<td align="center" valign="top">0.0</td>
</tr>
<tr>
<td align="left" valign="top">     Miscellaneous/Not Specified</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">0.9</td>
<td align="center" valign="top">0.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Total</span></td>
<td align="center" valign="top"><span class="Bold">4.2</span></td>
<td align="center" valign="top"><span class="Bold">7.9</span></td>
<td align="center" valign="top"><span class="Bold">3.7</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="Bold">Other Malignancy</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">3.2</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">3.3</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1.9</span></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a4c2e66-fbe5-48a0-a9cf-77283d25f435"></a><a name="section-6.3"></a><p></p>
<h2>6.3 High-Immunologic Risk Patients </h2>
<p class="First">Safety was assessed in 224 patients who received at least one dose of sirolimus with cyclosporine [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_84a817be-e3ad-4544-88f6-3758a95edd14">14.3</a>)</span>]. Overall, the incidence and nature of adverse events was similar to those seen in previous combination studies with Rapamune. The incidence of malignancy was 1.3% at 12 months. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5f8cfd9-646a-4928-a7ce-2bad0daaf4e8"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Conversion from Calcineurin Inhibitors to Rapamune in Maintenance Renal Transplant Population </h2>
<p class="First">The safety and efficacy of conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant population have not been established [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_9b21560b-a9b0-4fac-99a3-2fe516c6bc25">14.4</a>)</span>]. In an ongoing study evaluating the safety and efficacy of conversion from calcineurin inhibitors to Rapamune (initial target sirolimus concentrations of 12-20 ng/mL, and then 8-20 ng/mL, by chromatographic assay) in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n = 87) with a baseline glomerular filtration rate of less than 40 mL/min. There was a higher rate of serious adverse events, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, acute rejection, graft loss and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in this stratum of the Rapamune treatment arm. </p>
<p>The subset of patients with a baseline glomerular filtration rate of less than 40 mL/min had 2 years of follow-up after randomization. In this population, the rate of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> was 15/58 vs. 4/29, graft loss (excluding <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> with functioning graft loss) was 13/58 vs. 9/29, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 9/58 vs. 1/29 in the sirolimus conversion group and CNI continuation group, respectively. </p>
<p>In the subset of patients with a baseline glomerular filtration rate of greater than 40 mL/min, there was no benefit associated with conversion with regard to improvement in renal function and a greater incidence of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the Rapamune conversion arm.</p>
<p>Overall in this study, a 5-fold increase in the reports of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> among sirolimus (11/551) and comparator (1/273) treatment groups was observed with 2:1 randomization scheme.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_575660ad-6d6c-4d30-832f-f48d9feaa450"></a><a name="section-6.5"></a><p></p>
<h2>6.5 Pediatrics </h2>
<p class="First">Safety was assessed in a controlled clinical trial in pediatric (&lt; 18 years of age) renal transplant patients considered at high-immunologic risk, defined as a history of one or more <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span> episodes and/or the presence of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span> on a renal biopsy [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_4f02c26f-b0c0-4ff6-911e-9a8d569ea51f">14.5</a>)</span>]. The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with a higher incidence of deterioration of renal function (creatinine increased) compared to calcineurin inhibitor-based therapy, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>), and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb1b4701-d5a1-4996-9621-15fd59427022"></a><a name="section-6.6"></a><p></p>
<h2>6.6 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Rapamune. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<ul>
<li>
<span class="Bold"><span class="Italics">Body as a Whole</span></span> – <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">Lymphedema</span>. </li>
<li>
<span class="Bold"><span class="Italics">Cardiovascular</span></span> – <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span> (including hemodynamically significant <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusions</span> and tamponade requiring intervention in children and adults).</li>
<li>
<span class="Bold"><span class="Italics">Hematological/Lymphatic</span></span> – The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced HUS/TTP/TMA (see <span class="Italics">Warnings and Precautions </span><span class="Italics">(<a href="#i4i_section_id_8e82a9e2-0685-46a3-88b5-0ddcdc3681eb">5.12</a>)</span>]; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. </li>
<li>
<span class="Bold"><span class="Italics">Hepatobiliary Disorders</span></span> – Hepatotoxicity, including fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, with elevated sirolimus trough concentrations. </li>
<li>
<span class="Bold"><span class="Italics">Immune System</span></span> – <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7">5.4</a>)</span>]. </li>
<li>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span> – <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span>. </li>
<li>
<span class="Bold"><span class="Italics">Metabolic/Nutritional</span></span> – <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function test abnormal</span>, AST/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, ALT/SGPT increased, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. </li>
<li>
<span class="Bold"><span class="Italics">Respiratory</span></span> – Cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span> <span class="product-label-link" type="condition" conceptid="4045260" conceptname="Bronchiolitis obliterans organizing pneumonia">organizing pneumonia</span> [BOOP], and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>), some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including Rapamune. In some cases, the <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> has resolved upon discontinuation or dose reduction of Rapamune. The risk may be increased as the sirolimus trough concentration increases [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2ff38354-8cea-41b3-a7ea-edc42b92a96b">5.10</a>)</span>]; <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>; <span class="product-label-link" type="condition" conceptid="435853" conceptname="Pulmonary alveolar proteinosis">alveolar proteinosis</span></li>
<li>
<span class="Bold"><span class="Italics">Skin</span></span> – <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> [see <span class="Italics">Warnings and Precautions</span><span class="Italics"> (<a href="#i4i_section_id_2174b935-9605-4106-9545-45754ab4cca7">5.4</a>)</span>]. </li>
<li>
<span class="Bold"><span class="Italics">Urogenital</span></span> – <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="4030513" conceptname="Focal segmental glomerulosclerosis">focal segmental glomerulosclerosis</span>. <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">Azoospermia</span> has been reported with the use of Rapamune and has been reversible upon discontinuation of Rapamune in most cases.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_1c063075-59e7-474f-86f7-4d966060d10c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Sirolimus is known to be a substrate for both cytochrome P‑450 3A4 (CYP3A4) and p‑glycoprotein (P‑gp). Inducers of CYP3A4 and P‑gp may decrease sirolimus concentrations whereas inhibitors of CYP3A4 and P‑gp may increase sirolimus concentrations. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7b1abd2-b040-4ca6-97ac-a9220528d63b"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Use with Cyclosporine </h2>
<p class="First">Cyclosporine, a substrate and inhibitor of CYP3A4 and P‑gp, was demonstrated to increase sirolimus concentrations when co‑administered with sirolimus. In order to diminish the effect of this interaction with cyclosporine, it is recommended that Rapamune be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and/or cyclosporine capsules (MODIFIED). If cyclosporine is withdrawn from combination therapy with Rapamune, higher doses of Rapamune are needed to maintain the recommended sirolimus trough concentration ranges [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_9f366ab2-0574-4ab9-bf22-17ed85628dd4">2.1</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfffc254-2e96-4de1-8a9b-95d12c2e2cde"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Strong Inducers and Strong Inhibitors of CYP3A4 and P-gp </h2>
<p class="First">Avoid concomitant use of sirolimus with strong inducers (e.g., rifampin, rifabutin) and strong inhibitors (e.g., ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin) of CYP3A4 and P-gp. Alternative agents with lesser interaction potential with sirolimus should be considered [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2">5.16</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0edaea58-d281-4a3e-a3fe-22c204ce1105"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Grapefruit Juice </h2>
<p class="First">Because grapefruit juice inhibits the CYP3A4-mediated metabolism of sirolimus, it must not be taken with or be used for dilution of Rapamune [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_b2bc958b-4da7-4c76-a8b3-afb4e3f13c1e">2.7</a>)</span>, <span class="Italics">Drug Interactions (<a href="#i4i_section_id_0edaea58-d281-4a3e-a3fe-22c204ce1105">7.3</a>)</span>, <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd6972d4-0b36-4b71-aeed-17e65ef77bbe"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Inducers or Inhibitors of CYP3A4 and P-gp </h2>
<p class="First">Exercise caution when using sirolimus with drugs or agents that are modulators of CYP3A4 and P-gp. The dosage of Rapamune and/or the co-administered drug may need to be adjusted [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
<ul>
<li>
<span class="Italics">Drugs that could increase sirolimus blood concentrations:<br></span>Bromocriptione, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, HIV‑protease inhibitors (e.g., ritonavir, indinavir), metoclopramide, nicardipine, troleandomycin, verapamil </li>
<li>
<span class="Italics">Drugs and other agents that could decrease sirolimus concentrations:<br></span>Carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort (<span class="Italics">Hypericum perforatum</span>) </li>
<li>
<span class="Italics">Drugs with concentrations that could increase when given with Rapamune:</span><br>Verapamil </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a7567e2-5a24-4a75-92ce-a8ce79f5e6f4"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Vaccination </h2>
<p class="First">Immunosuppressants may affect response to vaccination. Therefore, during treatment with Rapamune, vaccination may be less effective. The use of live vaccines should be avoided; live vaccines may include, but are not limited to, the following: <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span>, BCG, <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and TY21a <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_2545003e-6a0a-4f55-89e4-ffdf193cd7bf"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_dcd4bbbf-cffc-4c9c-a7b4-85c4c9b47208"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: Sirolimus was embryo/fetotoxic in rats when given in doses approximately 0.2 to 0.5 the human doses (adjusted for body surface area). Embryo/fetotoxicity was manifested as mortality and reduced fetal weights (with associated delays in skeletal ossification). However, no teratogenesis was evident. In combination with cyclosporine, rats had increased embryo/feto mortality compared with sirolimus alone. There were no effects on rabbit development at a maternally toxic dosage approximately 0.3 to 0.8 times the human doses (adjusted for body surface area). There are no adequate and well‑controlled studies in pregnant women. Effective contraception must be initiated before Rapamune therapy, during Rapamune therapy, and for 12 weeks after Rapamune therapy has been stopped. Rapamune should be used during pregnancy only if the potential benefit outweighs the potential risk to the embryo/fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_bd963888-9783-45f0-bf20-fbfff25ecebf"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Sirolimus is excreted in trace amounts in milk of lactating rats. It is not known whether sirolimus is excreted in human milk. The pharmacokinetic and safety profiles of sirolimus in infants are not known. Because many drugs are excreted in human milk, and because of the potential for adverse reactions in nursing infants from sirolimus, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_91fab014-d1ab-4bd6-94d6-9f4a4b6fb9c6"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of Rapamune in pediatric patients &lt; 13 years have not been established. </p>
<p>The safety and efficacy of Rapamune Oral Solution and Rapamune Tablets have been established in children ≥ 13 years judged to be at low- to moderate-immunologic risk. Use of Rapamune Oral Solution and Rapamune Tablets in this subpopulation of children ≥ 13 years is supported by evidence from adequate and well-controlled trials of Rapamune Oral Solution in adults with additional pharmacokinetic data in pediatric renal transplantation patients [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
<p>Safety and efficacy information from a controlled clinical trial in pediatric and adolescent (&lt; 18 years of age) renal transplant patients judged to be at high-immunologic risk, defined as a history of one or more acute rejection episodes and/or the presence of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span>, do not support the chronic use of Rapamune Oral Solution or Tablets in combination with calcineurin inhibitors and corticosteroids, due to the higher incidence of lipid abnormalities and deterioration of renal function associated with these immunosuppressive regimens compared to calcineurin inhibitors, without increased benefit with respect to acute rejection, graft survival, or patient survival [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_4f02c26f-b0c0-4ff6-911e-9a8d569ea51f">14.5</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_3513f1c3-b3de-4687-b0ec-45667848e297"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Rapamune Oral Solution or Tablets did not include sufficient numbers of patients ≥ 65 years to determine whether they respond differently from younger patients. Data pertaining to sirolimus trough concentrations suggest that dose adjustments based upon age in geriatric renal patients are not necessary. Differences in responses between the elderly and younger patients have not been identified. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, or cardiac function, and of concomitant disease or other drug therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2139620b-c685-4e9b-8f9f-b9cc5512570d"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">The maintenance dose of Rapamune should be reduced in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_2dd1f681-9297-43ad-825d-125c61cd3b3f">2.5</a>)</span>, <span class="Italics">Clinical Pharmacology</span><span class="Italics"> (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bad18db-9b1a-4e1c-a278-7e3d52aacc13"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Dosage adjustment is not required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_723c0e3d-3e11-4628-8e20-9e8a81f3cf3f">2.6</a>)</span>, <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b9da48e5-ecc6-4749-ba8b-e6724b13a87a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Rapamune have been received; however, experience has been limited. In general, the adverse effects of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are consistent with those listed in the adverse reactions section [see <span class="Italics">Adverse Reactions (<a href="#i4i_adverse_effects_id_7a92e608-7d7a-4ddd-8e82-fbb370dba16b">6</a>)</span>]. </p>
<p>General supportive measures should be followed in all cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Based on the low aqueous solubility and high erythrocyte and plasma protein binding of sirolimus, it is anticipated that sirolimus is not dialyzable to any significant extent. In mice and rats, the acute oral LD<span class="Sub">50</span> was greater than 800 mg/kg. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_72db429e-6542-4dbb-ac33-214a82bd4b30"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by <span class="Italics">Streptomyces hygroscopicus</span>. The chemical name of sirolimus (also known as rapamycin) is (3<span class="Italics">S</span>,6<span class="Italics">R</span>,7<span class="Italics">E</span>,9<span class="Italics">R</span>,10<span class="Italics">R</span>,12<span class="Italics">R</span>,14<span class="Italics">S</span>,15<span class="Italics">E</span>,17<span class="Italics">E</span>,19<span class="Italics">E</span>,21<span class="Italics">S</span>,23<span class="Italics">S</span>,26<span class="Italics">R</span>,27<span class="Italics">R</span>,34a<span class="Italics">S</span>)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34, 34a-hexadecahydro-9,27-dihydroxy-3-[(1<span class="Italics">R</span>)-2-[(1<span class="Italics">S</span>,3<span class="Italics">R</span>,4<span class="Italics">R</span>)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3<span class="Italics">H</span>-pyrido[2,1-c][1,4] oxaazacyclohentriacontine-1,5,11,28,29 (4<span class="Italics">H</span>,6<span class="Italics">H</span>,31<span class="Italics">H</span>)-pentone. Its molecular formula is C<span class="Sub">51</span>H<span class="Sub">79</span>NO<span class="Sub">13</span> and its molecular weight is 914.2. The structural formula of sirolimus is illustrated as follows. </p>
<div class="Figure"><img alt="Rapamune Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-01.jpg"></div>
<p>Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile. </p>
<p>Rapamune is available for administration as an oral solution containing 1 mg/mL sirolimus. Rapamune is also available as a white, triangular-shaped tablet containing 1 mg sirolimus, and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus. </p>
<p>The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG<span class="Sup">®</span> (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol. </p>
<p>The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze, talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene glycol 20,000, glyceryl monooleate, carnauba wax, <span class="Italics">dl</span>-alpha tocopherol, and other ingredients. The 2 mg dosage strength also contains iron oxide yellow 10 and iron oxide brown 70. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e23dc666-55a4-4103-9962-8e627602d933"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_e4020d71-9776-4ced-97e5-e47575404856"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G<span class="Sub">1</span> to the S phase of the cell cycle. </p>
<p>Studies in experimental models show that sirolimus prolongs allograft (kidney, heart, skin, islet, small bowel, pancreatico-duodenal, and bone marrow) survival in mice, rats, pigs, and/or primates. Sirolimus reverses acute rejection of heart and kidney allografts in rats and prolongs the graft survival in presensitized rats. In some studies, the immunosuppressive effect of sirolimus lasts up to 6 months after discontinuation of therapy. This tolerization effect is alloantigen-specific. </p>
<p>In rodent models of autoimmune disease, sirolimus suppresses immune-mediated events associated with <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, collagen-induced <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, autoimmune type I <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, autoimmune <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, experimental allergic <span class="product-label-link" type="condition" conceptid="373189" conceptname="Encephalomyelitis">encephalomyelitis</span>, graft-versus-host disease, and autoimmune uveoretinitis. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_caf2af23-3b73-4c0a-9bb8-db5be8fe4164"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Orally-administered Rapamune, at doses of 2 mg/day and 5 mg/day, significantly reduced the incidence of organ rejection in low- to moderate-immunologic risk renal transplant patients at 6 months following transplantation compared with either azathioprine or placebo [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_194bfdb6-af73-4213-ad64-5dcdfb1cf70e">14.1</a>)</span>]. There was no demonstrable efficacy advantage of a daily maintenance dose of 5 mg with a loading dose of 15 mg over a daily maintenance dose of 2 mg with a loading dose of 6 mg. Therapeutic drug monitoring should be used to maintain sirolimus drug levels within the target-range [see <span class="Italics">Dosage and Administration</span><span class="Italics"> (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Sirolimus pharmacokinetics activity have been determined following oral administration in healthy subjects, pediatric patients, hepatically impaired patients, and renal transplant patients. </p>
<p>The pharmacokinetic parameters of sirolimus in low- to moderate-immunologic risk adult renal transplant patients following multiple dosing with Rapamune 2 mg daily, in combination with cyclosporine and corticosteroids, is summarized in the following <a href="#id_4a3426ee-e27b-4eb7-b239-c1ac43da3db2">table</a>. </p>
<a name="id_4a3426ee-e27b-4eb7-b239-c1ac43da3db2"></a><table width="430.000">
<caption><span>MEAN ± SD STEADY STATE SIROLIMUS PHARMACOKINETIC PARAMETERS IN LOW- TO MODERATE-IMMUNOLOGIC RISK ADULT RENAL TRANSPLANT PATIENTS FOLLOWING RAPAMUNE 2 MG DAILY<span class="Sup">a,b</span></span></caption>
<col align="left" width="44.4%">
<col align="left" width="27.0%">
<col align="left" width="28.6%">
<thead>
<tr class="First Toprule">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top">Multiple Dose (daily dose)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"></td>
<td align="center" valign="top">Solution</td>
<td align="center" valign="top">Tablets</td>
</tr>
</thead>
<tfoot><tr class="Last"><td align="left" colspan="3" valign="top"><p class="First">a: In presence of cyclosporine administered 4 hours before Rapamune dosing.<br>b: Based on data collected at months 1 and 3 post-transplantation. <br>c: Average C<span class="Sub">min</span> over 6 months.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Toprule" align="center" valign="top">14.4 ± 5.3</td>
<td align="center" valign="top">15.0 ± 4.9</td>
</tr>
<tr>
<td align="left" valign="top">t<span class="Sub">max</span> (hr)</td>
<td align="center" valign="top">2.1 ± 0.8</td>
<td align="center" valign="top">3.5 ± 2.4</td>
</tr>
<tr>
<td align="left" valign="top">AUC (ng•h/mL)</td>
<td align="center" valign="top">194 ± 78</td>
<td align="center" valign="top">230 ± 67</td>
</tr>
<tr>
<td align="left" valign="top">C<span class="Sub">min</span> (ng/mL)<span class="Sup">c</span>
</td>
<td align="center" valign="top">7.1 ± 3.5</td>
<td align="center" valign="top">7.6 ± 3.1</td>
</tr>
<tr class="Last">
<td align="left" valign="top">CL/F (mL/h/kg)</td>
<td align="center" valign="top">173 ± 50</td>
<td align="center" valign="top">139 ± 63</td>
</tr>
</tbody>
</table>
<p>Whole blood trough sirolimus concentrations, as measured by LC/MS/MS in renal transplant patients, were significantly correlated with AUC<span class="Sub">τ,ss</span>. Upon repeated, twice-daily administration without an initial loading dose in a multiple-dose study, the average trough concentration of sirolimus increases approximately 2- to 3-fold over the initial 6 days of therapy, at which time steady-state is reached. A loading dose of 3 times the maintenance dose will provide near steady-state concentrations within 1 day in most patients [see <span class="Italics">Dosage and Administration (<a href="#i4i_dosage_admin_id_5e54ea17-e064-481b-b328-d830e125bc89">2</a>, <a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>), Warning and Precautions (<a href="#i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f">5.14</a>)</span>]. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f991376e-671b-4ece-9cd4-fa1f144bdd11"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Italics"><span class="Underline">Absorption</span></span></h3>
<p class="First">Following administration of Rapamune Oral Solution, the mean times to peak concentration (t<span class="Sub">max</span>) of sirolimus are approximately 1 hour and 2 hours in healthy subjects and renal transplant patients, respectively. The systemic availability of sirolimus is low, and was estimated to be approximately 14% after the administration of Rapamune Oral Solution. In healthy subjects, the mean bioavailability of sirolimus after administration of the tablet is approximately 27% higher relative to the solution. Sirolimus tablets are not bioequivalent to the solution; however, clinical equivalence has been demonstrated at the 2 mg dose level. Sirolimus concentrations, following the administration of Rapamune Oral Solution to stable renal transplant patients, are dose-proportional between 3 and 12 mg/m<span class="Sup">2</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91234dc9-29cf-4fa6-b1de-bd880a34a40e"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Italics"><span class="Underline">Food Effects</span></span></h3>
<p class="First">To minimize variability in sirolimus concentrations, both Rapamune Oral Solution and Tablets should be taken consistently with or without food [see <span class="Italics">Dosage and Administration (<a href="#i4i_dosage_admin_id_5e54ea17-e064-481b-b328-d830e125bc89">2</a>)</span>]. In healthy subjects, a high-fat meal (861.8 kcal, 54.9% kcal from fat) increased the mean total exposure (AUC) of sirolimus by 23 to 35%, compared with fasting. The effect of food on the mean sirolimus C<span class="Sub">max</span> was inconsistent depending on the Rapamune dosage form evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4f516e4-ada9-46d4-82e3-05337e27ddc7"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Italics"><span class="Underline">Distribution</span></span></h3>
<p class="First">The mean (± SD) blood-to-plasma ratio of sirolimus was 36 ± 18 in stable renal allograft patients, indicating that sirolimus is extensively partitioned into formed blood elements. The mean volume of distribution (Vss/F) of sirolimus is 12 ± 8 L/kg. Sirolimus is extensively bound (approximately 92%) to human plasma proteins, mainly serum albumin (97%), α<span class="Sub">1</span>-acid glycoprotein, and lipoproteins. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_63a902ac-d960-445b-8c99-9e173ebd6c34"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Italics"><span class="Underline">Metabolism</span></span></h3>
<p class="First">Sirolimus is a substrate for both CYP3A4 and P-gp. Sirolimus is extensively metabolized in the intestinal wall and liver and undergoes counter-transport from enterocytes of the small intestine into the gut lumen. Inhibitors of CYP3A4 and P-gp increase sirolimus concentrations. Inducers of CYP3A4 and P-gp decrease sirolimus concentrations [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2">5.16</a>)</span> and <span class="Italics">Drug Interactions </span><span class="Italics">(<a href="#i4i_interactions_id_1c063075-59e7-474f-86f7-4d966060d10c">7</a>)</span>]. Sirolimus is extensively metabolized by O‑demethylation and/or hydroxylation. Seven (7) major metabolites, including hydroxy, demethyl, and hydroxydemethyl, are identifiable in whole blood. Some of these metabolites are also detectable in plasma, fecal, and urine samples. Sirolimus is the major component in human whole blood and contributes to more than 90% of the immunosuppressive activity. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf53b607-2be1-49de-93b1-30588a969edc"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Italics"><span class="Underline">Excretion</span></span></h3>
<p class="First">After a single dose of [<span class="Sup">14</span>C] sirolimus oral solution in healthy volunteers, the majority (91%) of radioactivity was recovered from the feces, and only a minor amount (2.2%) was excreted in urine. The mean ± SD terminal elimination half life (t<span class="Sub">½</span>) of sirolimus after multiple dosing in stable renal transplant patients was estimated to be about 62 ± 16 hours. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54517dee-26f9-46b4-91a4-019e8637e7b1"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Italics"><span class="Underline">Sirolimus Concentrations (Chromatographic Equivalent) Observed in Phase 3 Clinical Studies</span></span></h3>
<p class="First">The <a href="#id_3ea1ccc3-d04d-4ef4-be9c-b67693c5d095">following</a> sirolimus concentrations (chromatographic equivalent) were observed in phase 3 clinical studies [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f">14</a>)</span>]. </p>
<a name="id_3ea1ccc3-d04d-4ef4-be9c-b67693c5d095"></a><table width="432.000">
<caption><span>SIROLIMUS WHOLE BLOOD TROUGH CONCENTRATIONS OBSERVED IN RENAL TRANSPLANT PATIENTS ENROLLED IN PHASE 3 STUDIES </span></caption>
<col align="left" width="17.6%">
<col align="left" width="27.8%">
<col align="left" width="13.7%">
<col align="left" width="13.7%">
<col align="left" width="13.7%">
<col align="left" width="13.7%">
<thead>
<tr class="First">
<td class="Botrule Toprule" align="left" rowspan="2" valign="top">Patient Population(Study number)</td>
<td class="Botrule" align="left" rowspan="2" valign="top">Treatment</td>
<td class="Botrule" align="center" colspan="2" valign="top">Year 1</td>
<td class="Botrule" align="center" colspan="2" valign="top">Year 3</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Mean<br>(ng/mL)</td>
<td class="Botrule" align="center" valign="top">10<span class="Sup">th</span> – 90<span class="Sup">th</span> percentiles<br>(ng/mL)</td>
<td class="Botrule" align="center" valign="top">Mean<br>(ng/mL)</td>
<td class="Botrule" align="center" valign="top">10<span class="Sup">th</span> – 90<span class="Sup">th</span> percentiles<br>(ng/mL)</td>
</tr>
</thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="6" valign="top"><p class="First">a: Months 4 through 12<br>b: Up to Week 2; observed CsA C<span class="Sub">min</span> was 217 (56 – 432) ng/mL <br>c: Week 2 to Week 26; observed CsA C<span class="Sub">min</span> range was 174 (71 – 288) ng/mL <br>d: Week 26 to Week 52; observed CsA C<span class="Sub">min</span> was 136 (54.5 – 218) ng/mL</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" rowspan="2" valign="top">Low-to-moderate risk(Studies 1 &amp; 2)</td>
<td class="Botrule" align="left" valign="top">Rapamune<br> (2 mg/day) + CsA</td>
<td class="Botrule" align="center" valign="top">7.2</td>
<td class="Botrule" align="center" valign="top">3.6 – 11</td>
<td class="Botrule" align="center" valign="top">–</td>
<td class="Botrule" align="center" valign="top">–</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rapamune<br> (5 mg/day) + CsA</td>
<td class="Botrule" align="center" valign="top">14</td>
<td class="Botrule" align="center" valign="top">8 – 22</td>
<td class="Botrule" align="center" valign="top">–</td>
<td class="Botrule" align="center" valign="top">–</td>
</tr>
<tr>
<td class="Botrule" align="left" rowspan="2" valign="top">Low-to-moderate risk(Study 3)</td>
<td class="Botrule" align="left" valign="top">Rapamune + CsA</td>
<td class="Botrule" align="center" valign="top">8.6</td>
<td class="Botrule" align="center" valign="top">5 – 13<span class="Sup">a</span>
</td>
<td class="Botrule" align="center" valign="top">9.1</td>
<td class="Botrule" align="center" valign="top">5.4 – 14</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rapamune alone</td>
<td class="Botrule" align="center" valign="top">19</td>
<td class="Botrule" align="center" valign="top">14 – 22<span class="Sup">a</span>
</td>
<td class="Botrule" align="center" valign="top">16</td>
<td class="Botrule" align="center" valign="top">11 – 22</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">High risk(Study 4)</td>
<td class="Botrule" align="left" valign="top">Rapamune + CsA</td>
<td class="Botrule" align="center" valign="top">15.7<br>11.8<br>11.5</td>
<td class="Botrule" align="center" valign="top">5.4 – 27.3<span class="Sup">b</span><br>6.2 – 16.9<span class="Sup">c</span><br>6.3 – 17.3<span class="Sup">d</span>
</td>
<td class="Botrule" align="center" valign="top">–</td>
<td class="Botrule" align="center" valign="top">–</td>
</tr>
</tbody>
</table>
<p>The withdrawal of cyclosporine and concurrent increases in sirolimus trough concentrations to steady-state required approximately 6 weeks. Following cyclosporine withdrawal, larger Rapamune doses were required due to the absence of the inhibition of sirolimus metabolism and transport by cyclosporine and to achieve higher target sirolimus trough concentrations during concentration-controlled administration [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_9f366ab2-0574-4ab9-bf22-17ed85628dd4">2.1</a>), Drug Interactions (<a href="#i4i_section_id_f7b1abd2-b040-4ca6-97ac-a9220528d63b">7.1</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93908312-a827-44d3-9865-c0f980290aba"></a><a name="section-11.3.7"></a><p></p>
<h3><span class="Bold">Pharmacokinetics in Specific Populations</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c6bad8b-4ff2-47ca-9e1f-481f967d8951"></a><a name="section-11.3.7.1"></a><p></p>
<h4><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></h4>
<p class="First">Rapamune was administered as a single, oral dose to subjects with normal hepatic function and to patients with Child-Pugh classification A (mild), B (moderate), or C (severe) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Compared with the values in the normal hepatic function group, the patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had 43%, 94%, and 189% higher mean values for sirolimus AUC, respectively, with no statistically significant differences in mean C<span class="Sub">max</span>. As the severity of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> increased, there were steady increases in mean sirolimus t<span class="Sub">1/2</span>, and decreases in the mean sirolimus clearance normalized for body weight (CL/F/kg).</p>
<p>The maintenance dose of Rapamune should be reduced by approximately one third in patients with mild‑to‑moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and by approximately one half in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_2dd1f681-9297-43ad-825d-125c61cd3b3f">2.5</a>)</span>]. It is not necessary to modify the Rapamune loading dose in patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Therapeutic drug monitoring is necessary in all patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9f2a259-4026-4346-8a52-de0152036d6d"></a><a name="section-11.3.7.2"></a><p></p>
<h4><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></h4>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of sirolimus is not known. However, there is minimal (2.2%) renal excretion of the drug or its metabolites in healthy volunteers. The loading and the maintenance doses of Rapamune need not be adjusted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_723c0e3d-3e11-4628-8e20-9e8a81f3cf3f">2.6</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ad0f869-cf20-4511-b5e0-2401834042eb"></a><a name="section-11.3.7.3"></a><p></p>
<h4><span class="Italics"><span class="Underline">Pediatric</span></span></h4>
<p class="First">Sirolimus pharmacokinetic data were collected in concentration-controlled trials of pediatric renal transplant patients who were also receiving cyclosporine and corticosteroids. The target ranges for trough concentrations were either 10-20 ng/mL for the 21 children receiving tablets, or 5-15 ng/mL for the one child receiving oral solution. The children aged 6-11 years (n = 8) received mean ± SD doses of 1.75 ± 0.71 mg/day (0.064 ± 0.018 mg/kg, 1.65 ± 0.43 mg/m<span class="Sup">2</span>). The children aged 12-18 years (n = 14) received mean ± SD doses of 2.79 ± 1.25 mg/day (0.053 ± 0.0150 mg/kg, 1.86± 0.61 mg/m<span class="Sup">2</span>). At the time of sirolimus blood sampling for pharmacokinetic evaluation, the majority (80%) of these pediatric patients received the Rapamune dose at 16 hours after the once-daily cyclosporine dose. </p>
<a name="id_6ef3f56d-6ce4-4aca-814b-c36b9c5af179"></a><table width="430.000">
<caption><span>SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC RENAL TRANSPLANT PATIENTS (MULTIPLE-DOSE CONCENTRATION CONTROL)<span class="Sup">a,b</span></span></caption>
<col align="left" width="8.4%">
<col align="left" width="5.8%">
<col align="left" width="13.0%">
<col align="left" width="13.0%">
<col align="left" width="13.0%">
<col align="left" width="11.4%">
<col align="left" width="12.3%">
<col align="left" width="12.1%">
<col align="left" width="10.9%">
<thead><tr class="Botrule First Last">
<td align="center" valign="top">Age<br>(y)</td>
<td align="center" valign="top">n</td>
<td align="center" valign="top">Body<br>weight<br>(kg)</td>
<td align="center" valign="top">C<span class="Sub">max,ss</span><br>(ng/mL)</td>
<td align="center" valign="top">t<span class="Sub">max,ss</span><br>(h)</td>
<td align="center" valign="top">C<span class="Sub">min,ss</span><br>(ng/ml)</td>
<td align="center" valign="top">AUC<span class="Sub">τ,ss</span><br>(ng•h/mL)<br>
</td>
<td align="center" valign="top">CL/F<span class="Sup">c</span><br>(mL/h/kg)</td>
<td align="center" valign="top">CL/F<span class="Sup">c</span><br>(L/h/m<span class="Sup">2</span>)</td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="9" valign="top"><p class="First">a: Rapamune co-administered with cyclosporine oral solution [MODIFIED] (e.g., Neoral<span class="Sup">®</span> Oral Solution) and/or cyclosporine capsules [MODIFIED] (e.g., Neoral<span class="Sup">®</span> Soft Gelatin Capsules).<br>b: As measured by Liquid Chromatographic/Tandem <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Spectrometric Method (LC/MS/MS). <br>c: Oral-dose clearance adjusted by either body weight (kg) or body surface area (m<span class="Sup">2</span>). </p></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="center" valign="top">6-11</td>
<td class="Toprule" align="center" valign="top">8</td>
<td class="Toprule" align="center" valign="top">27 ± 10</td>
<td class="Toprule" align="center" valign="top">22.1 ± 8.9</td>
<td class="Toprule" align="center" valign="top">5.88 ± 4.05</td>
<td class="Toprule" align="center" valign="top">10.6 ± 4.3</td>
<td class="Toprule" align="center" valign="top">356 ± 127</td>
<td class="Toprule" align="center" valign="top">214 ± 129</td>
<td align="center" valign="top">5.4 ± 2.8</td>
</tr>
<tr class="Last">
<td align="center" valign="top">12-18</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">52 ± 15</td>
<td align="center" valign="top">34.5 ± 12.2</td>
<td align="center" valign="top">2.7 ± 1.5</td>
<td align="center" valign="top">14.7 ± 8.6</td>
<td align="center" valign="top">466 ± 236</td>
<td align="center" valign="top">136 ± 57</td>
<td align="center" valign="top">4.7 ± 1.9</td>
</tr>
</tbody>
</table>
<p>The <a href="#id_014d0fd4-7c9e-48d8-b66f-38b7513b0be4">table</a> below summarizes pharmacokinetic data obtained in pediatric dialysis patients with chronically <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
<a name="id_014d0fd4-7c9e-48d8-b66f-38b7513b0be4"></a><table width="431.000">
<caption><span>SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC PATIENTS WITH END-STAGE KIDNEY DISEASE MAINTAINED ON HEMODIALYSIS OR PERITONEAL DIALYSIS (1, 3, 9, 15 mg/m<span class="Sup">2</span> SINGLE DOSE)* </span></caption>
<col align="left" width="21.8%">
<col align="left" width="11.4%">
<col align="left" width="18.8%">
<col align="left" width="16.9%">
<col align="left" width="31.1%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top">Age Group (y)</td>
<td class="Botrule" align="left" valign="top">n</td>
<td class="Botrule" align="left" valign="top">t<span class="Sub">max</span> (h)</td>
<td class="Botrule" align="left" valign="top">t<span class="Sub">1/2</span> (h)</td>
<td class="Botrule" align="left" valign="top">CL/F/WT (mL/h/kg)</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top"><p class="First">* All subjects received Rapamune Oral Solution. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">5-11</td>
<td class="Toprule" align="left" valign="top">9</td>
<td class="Toprule" align="left" valign="top">1.1 ± 0.5</td>
<td class="Toprule" align="left" valign="top">71 ± 40</td>
<td align="left" valign="top">580 ± 450</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">12-18</td>
<td class="Botrule" align="left" valign="top">11</td>
<td class="Botrule" align="left" valign="top">0.79 ± 0.17</td>
<td class="Botrule" align="left" valign="top">55 ± 18</td>
<td class="Botrule" align="left" valign="top">450 ± 232</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc7589b9-01a5-4584-964b-fafc3a8a4a93"></a><a name="section-11.3.7.4"></a><p></p>
<h4><span class="Italics"><span class="Underline">Geriatric</span></span></h4>
<p class="First">Clinical studies of Rapamune did not include a sufficient number of patients &gt; 65 years of age to determine whether they will respond differently than younger patients. After the administration of Rapamune Oral Solution or Tablets, sirolimus trough concentration data in renal transplant patients &gt; 65 years of age were similar to those in the adult population 18 to 65 years of age. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3328d97f-647d-4919-9144-5e7866ab237d"></a><a name="section-11.3.7.5"></a><p></p>
<h4><span class="Italics"><span class="Underline">Gender</span></span></h4>
<p class="First">Sirolimus clearance in males was 12% lower than that in females; male subjects had a significantly longer t<span class="Sub">1/2</span> than did female subjects (72.3 hours versus 61.3 hours). Dose adjustments based on gender are not recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac13c44b-2c80-4b24-96c0-74f4c193be5f"></a><a name="section-11.3.7.6"></a><p></p>
<h4><span class="Italics"><span class="Underline">Race</span></span></h4>
<p class="First">In the phase 3 trials using Rapamune solution or tablets and cyclosporine oral solution [MODIFIED] (e.g., Neoral<span class="Sup">®</span> Oral Solution) and/or cyclosporine capsules [MODIFIED] (e.g., Neoral<span class="Sup">®</span> Soft Gelatin Capsules) [see <span class="Italics">Clinical Studies (<a href="#i4i_section_id_1cd1294b-0e2c-46d5-b585-69e7cf2f250f">14</a>)</span>], there were no significant differences in mean trough sirolimus concentrations over time between Black (n = 190) and non-Black (n = 852) patients during the first 6 months after transplantation. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0aa2c1f3-b3f7-4ffe-ad0e-bc869f9ef07b"></a><a name="section-11.3.8"></a><p></p>
<h3><span class="Bold">Drug-Drug Interactions </span></h3>
<p class="First">Sirolimus is known to be a substrate for both cytochrome CYP3A4 and P-gp. The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between sirolimus and concomitantly administered drugs is discussed below. Drug interaction studies have not been conducted with drugs other than those described below. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_715155ba-552b-4404-ade5-5213ccc4b069"></a><a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Italics">Cyclosporine:</span> Cyclosporine is a substrate and inhibitor of CYP3A4 and P-gp. Sirolimus should be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and/or cyclosporine capsules (MODIFIED). Sirolimus concentrations may decrease when cyclosporine is discontinued, unless the Rapamune dose is increased [see <span class="Italics">Dosage and Administration (<a href="#i4i_mechanism_action_id_e4020d71-9776-4ced-97e5-e47575404856">2.1</a>), Drug Interactions (<a href="#i4i_section_id_f7b1abd2-b040-4ca6-97ac-a9220528d63b">7.1</a>)</span>]. </p>
<p>In a single-dose drug-drug interaction study, 24 healthy volunteers were administered 10 mg Rapamune Tablets either simultaneously or 4 hours after a 300-mg dose of Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). For simultaneous administration, mean C<span class="Sub">max</span> and AUC were increased by 512% and 148%, respectively, relative to administration of sirolimus alone. However, when given 4 hours after cyclosporine administration, sirolimus C<span class="Sub">max</span> and AUC were both increased by only 33% compared with administration of sirolimus alone. </p>
<p>In a single dose drug-drug interaction study, 24 healthy volunteers were administered 10 mg Rapamune Oral Solution either simultaneously or 4 hours after a 300 mg dose of Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). For simultaneous administration, the mean C<span class="Sub">max</span> and AUC of sirolimus<span class="Bold">,</span> following simultaneous administration were increased by 116% and 230%, respectively, relative to administration of sirolimus alone. However, when given 4 hours after Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]) administration, sirolimus C<span class="Sub">max</span> and AUC were increased by only 37% and 80%, respectively, compared with administration of Rapamune alone. </p>
<p>In a single-dose cross-over drug-drug interaction study, 33 healthy volunteers received 5 mg Rapamune Oral Solution alone, 2 hours before, and 2 hours after a 300 mg dose of Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). When given 2 hours before Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]) administration, sirolimus C<span class="Sub">max</span> and AUC were comparable to those with administration of sirolimus alone. However, when given 2 hours after, the mean C<span class="Sub">max</span> and AUC of sirolimus were increased by 126% and 141%, respectively, relative to administration of sirolimus alone. </p>
<p>Mean cyclosporine C<span class="Sub">max</span> and AUC were not significantly affected when Rapamune Oral Solution was given simultaneously or when administered 4 hours after Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). However, after multiple-dose administration of sirolimus given 4 hours after Neoral<span class="Sup">®</span> in renal post-transplant patients over 6 months, cyclosporine oral-dose clearance was reduced, and lower doses of Neoral<span class="Sup">®</span> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]) were needed to maintain target cyclosporine concentration. </p>
<p>In a multiple-dose study in 150 <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> patients, sirolimus 0.5, 1.5, and 3 mg/m<span class="Sup">2</span>/day was administered simultaneously with Sandimmune<span class="Sup">®</span> Oral Solution (cyclosporine Oral Solution) 1.25 mg/kg/day. The increase in average sirolimus trough concentrations ranged between 67% to 86% relative to when Rapamune was administered without cyclosporine. The intersubject variability (% CV) for sirolimus trough concentrations ranged from 39.7% to 68.7%. There was no significant effect of multiple-dose sirolimus on cyclosporine trough concentrations following Sandimmune<span class="Sup">®</span> Oral Solution (cyclosporine oral solution) administration. However, the % CV was higher (range 85.9% - 165%) than those from previous studies. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_984bb3f2-012c-49d5-b8e7-a2f21e86afdb"></a><a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Italics">Diltiazem:</span> Diltiazem is a substrate and inhibitor of CYP3A4 and P-gp; sirolimus concentrations should be monitored and a dose adjustment may be necessary [see <span class="Italics">Drug Interactions (<a href="#i4i_section_id_bd6972d4-0b36-4b71-aeed-17e65ef77bbe">7.4</a>)</span>]. The simultaneous oral administration of 10 mg of sirolimus oral solution and 120 mg of diltiazem to 18 healthy volunteers significantly affected the bioavailability of sirolimus. Sirolimus C<span class="Sub">max</span>, t<span class="Sub">max</span>, and AUC were increased 1.4-, 1.3-, and 1.6-fold, respectively. Sirolimus did not affect the pharmacokinetics of either diltiazem or its metabolites desacetyldiltiazem and desmethyldiltiazem. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc413763-6eb6-48e2-a0d6-7547fd5c6903"></a><a name="section-11.3.11"></a><p></p>
<p class="First"><span class="Italics">Erythromycin:</span> Erythromycin is a substrate and inhibitor of CYP3A4 and P-gp; co-administration of sirolimus oral solution or tablets and erythromycin is not recommended [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2">5.16</a>), Drug Interactions (<a href="#i4i_section_id_bfffc254-2e96-4de1-8a9b-95d12c2e2cde">7.2</a>)</span>]. The simultaneous oral administration of 2 mg daily of sirolimus oral solution and 800 mg q 8h of erythromycin as erythromycin ethylsuccinate tablets at steady state to 24 healthy volunteers significantly affected the bioavailability of sirolimus and erythromycin. Sirolimus C<span class="Sub">max</span> and AUC were increased 4.4- and 4.2-fold respectively and t<span class="Sub">max</span> was increased by 0.4 hr. Erythromycin C<span class="Sub">max</span> and AUC were increased 1.6- and 1.7-fold, respectively, and t<span class="Sub">max</span> was increased by 0.3 hr. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dca34799-1b8d-4776-a62e-235849f7dd48"></a><a name="section-11.3.12"></a><p></p>
<p class="First"><span class="Italics">Ketoconazole:</span> Ketoconazole is a strong inhibitor of CYP3A4 and P-gp; co-administration of sirolimus oral solution or tablets and ketoconazole is not recommended [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2">5.16</a>), Drug Interactions (<a href="#i4i_section_id_bfffc254-2e96-4de1-8a9b-95d12c2e2cde">7.2</a>)</span>]. Multiple-dose ketoconazole administration significantly affected the rate and extent of absorption and sirolimus exposure after administration of Rapamune Oral Solution, as reflected by increases in sirolimus C<span class="Sub">max</span>, t<span class="Sub">max</span>, and AUC of 4.3-fold, 38%, and 10.9-fold, respectively. However, the terminal t<span class="Sub">½</span> of sirolimus was not changed. Single-dose sirolimus did not affect steady-state 12-hour plasma ketoconazole concentrations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b513d92a-6248-4121-b83b-dcfdf9019b09"></a><a name="section-11.3.13"></a><p></p>
<p class="First"><span class="Italics">Rifampin:</span> Rifampin is a strong inducer of CYP3A4 and P-gp; co-administration of Rapamune oral solution or tablets and rifampin is not recommended. In patients where rifampin is indicated, alternative therapeutic agents with less enzyme induction potential should be considered [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2">5.16</a>), Drug Interactions (<a href="#i4i_section_id_bfffc254-2e96-4de1-8a9b-95d12c2e2cde">7.2</a>)</span>]. Pretreatment of 14 healthy volunteers with multiple doses of rifampin, 600 mg daily for 14 days, followed by a single 20-mg dose of sirolimus oral solution, greatly decreased sirolimus AUC and C<span class="Sub">max</span> by about 82% and 71%, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_787a1600-0609-4029-9759-68a71469d4d7"></a><a name="section-11.3.14"></a><p></p>
<p class="First"><span class="Italics">Verapamil:</span> Verapamil is a substrate and inhibitor of CYP3A4 and P-gp; sirolimus concentrations should be monitored and a dose adjustment may be necessary; [see <span class="Italics">Drug Interactions (<a href="#i4i_section_id_bd6972d4-0b36-4b71-aeed-17e65ef77bbe">7.4</a>)</span>]. The simultaneous oral administration of 2 mg daily of sirolimus oral solution and 180 mg q 12h of verapamil at steady state to 26 healthy volunteers significantly affected the bioavailability of sirolimus and verapamil. Sirolimus C<span class="Sub">max</span> and AUC were increased 2.3- and 2.2-fold, respectively, without substantial change in t<span class="Sub">max</span>. The C<span class="Sub">max</span> and AUC of the pharmacologically active S(-) enantiomer of verapamil were both increased 1.5-fold and t<span class="Sub">max</span> was decreased by 1.2 hr. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2862631b-bbe8-4413-9ff7-d0975e3aca9b"></a><a name="section-11.3.15"></a><p></p>
<h3><span class="Bold">Drugs Which May Be Co-administered Without Dose Adjustment</span></h3>
<p class="First">Clinically significant pharmacokinetic drug-drug interactions were not observed in studies of drugs listed below. Sirolimus and these drugs may be co-administered without dose adjustments. </p>
<p><span class="Italics">Acyclovir</span><br><span class="Italics">Atorvastatin</span><br><span class="Italics">Digoxin</span><br><span class="Italics">Glyburide</span><br><span class="Italics">Nifedipine</span><br><span class="Italics">Norgestrel/ethinyl estradiol (Lo/Ovral</span><span class="Sup">®</span><span class="Italics">)</span><br><span class="Italics">Prednisolone</span><br><span class="Italics">Sulfamethoxazole/trimethoprim (Bactrim</span><span class="Sup">®</span><span class="Italics">)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57035eed-5116-48e8-974a-6a8dd5e56874"></a><a name="section-11.3.16"></a><p></p>
<h3><span class="Bold">Other Drug-Drug Interactions</span></h3>
<p class="First">Co-administration of Rapamune with other known strong inhibitors of CYP3A4 and/or P-gp (such as voriconazole, itraconazole, telithromycin, or clarithromycin) or other known strong inducers of CYP3A4 and/or P-gp (such as rifabutin) is not recommended [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_6d29c413-a036-4d2c-a191-12b7db58c0a2">5.16</a>), Drug Interactions (<a href="#i4i_section_id_bfffc254-2e96-4de1-8a9b-95d12c2e2cde">7.2</a>)</span>]. In patients in whom strong inhibitors or inducers of CYP3A4 are indicated, alternative therapeutic agents with less potential for inhibition or induction of CYP3A4 should be considered. </p>
<p>Care should be exercised when drugs or other substances that are substrates and/or inhibitors or inducers of CYP3A4 are administered concomitantly with Rapamune. Other drugs that have the potential to increase sirolimus blood concentrations include (but are not limited to): </p>
<p><span class="Italics">Calcium channel blockers: nicardipine.</span><br><span class="Italics">Antifungal agents: clotrimazole, fluconazole.</span><br><span class="Italics">Antibiotics: troleandomycin.</span><br><span class="Italics">Gastrointestinal prokinetic agents: cisapride, metoclopramide.</span><br><span class="Italics">Other drugs: bromocriptine, cimetidine, danazol, HIV-protease inhibitors (e.g., ritonavir, indinavir).</span></p>
<p>Other drugs that have the potential to decrease sirolimus concentrations include (but are not limited to): </p>
<p><span class="Italics">Anticonvulsants: carbamazepine, phenobarbital, phenytoin.<br>Antibiotics: rifapentine.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bac233e2-1a1b-4b15-a80d-8d21c4988fae"></a><a name="section-11.3.17"></a><p></p>
<h3><span class="Bold">Other Drug-Food Interactions</span></h3>
<p class="First">Grapefruit juice reduces CYP3A4-mediated drug metabolism. Grapefruit juice must not be taken with or used for dilution of Rapamune [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_b2bc958b-4da7-4c76-a8b3-afb4e3f13c1e">2.7</a>), Drug Interactions (<a href="#i4i_section_id_0edaea58-d281-4a3e-a3fe-22c204ce1105">7.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46864ec1-4011-4e9f-9c4e-dfcaaf82146c"></a><a name="section-11.3.18"></a><p></p>
<h3><span class="Bold">Drug-Herb Interactions</span></h3>
<p class="First">St. John's Wort (<span class="Italics">hypericum perforatum</span>) induces CYP3A4 and P-gp. Since sirolimus is a substrate for both cytochrome CYP3A4 and P-gp, there is the potential that the use of St. John's Wort in patients receiving Rapamune could result in reduced sirolimus concentrations [see <span class="Italics">Drug Interactions (<a href="#i4i_section_id_bd6972d4-0b36-4b71-aeed-17e65ef77bbe">7.4</a>)</span>]. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_dd8e2d7e-a96e-4687-8abd-0cf9af116f8b"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_824ee589-b328-4225-8d8a-cfb0bf27a258"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies were conducted in mice and rats. In an 86-week female mouse study at sirolimus doses 30 to 120 times higher than the 2 mg daily clinical dose (adjusted for body surface area), there was a statistically significant increase in <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphoma</span> at all dose levels compared with controls. In a second mouse study at dosages that were approximately 3 to 16 times the clinical dose (adjusted for body surface area), <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> and carcinoma in males were considered sirolimus-related. In the 104-week rat study at dosages equal to or lower than the clinical dose of 2 mg daily (adjusted for body surface area), there were no significant findings. </p>
<p>Sirolimus was not genotoxic in the <span class="Italics">in vitro</span> bacterial reverse mutation assay, the Chinese hamster ovary cell chromosomal aberration assay, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation assay, or the <span class="Italics">in vivo</span> mouse micronucleus assay. </p>
<p>Fertility was diminished slightly in both male and female rats following oral administration of sirolimus at doses approximately 10 times or 2 times, respectively, the clinical dose of 2 mg daily (adjusted for body surface area). In male rats, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of testes, epididymides, prostate, seminiferous tubules and/or reduction in sperm counts were observed. In female rats, reduced size of ovaries and uteri was observed. Reduction of sperm count in male rats was reversible upon cessation of dosing in one study. Testicular tubular degeneration was also seen in a 4‑week intravenous study of sirolimus in monkeys at doses that were approximately equal to the clinical dose (adjusted for body surface area). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_d1c8db8b-91ac-4e5f-ae14-855176d29e51"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_194bfdb6-af73-4213-ad64-5dcdfb1cf70e"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Prophylaxis of Organ Rejection </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_363bd149-9f2c-4d67-bb1c-529acdf36e97"></a><a name="section-13.1.1"></a><p></p>
<h3><span class="Underline"><span class="Italics">Rapamune Oral Solution</span></span></h3>
<p class="First">The safety and efficacy of Rapamune Oral Solution for the prevention of organ rejection following renal transplantation were assessed in two randomized, double-blind, multicenter, controlled trials. These studies compared two dose levels of Rapamune Oral Solution (2 mg and 5 mg, once daily) with azathioprine (Study 1) or placebo (Study 2) when administered in combination with cyclosporine and corticosteroids. Study 1 was conducted in the United States at 38 sites. Seven hundred nineteen (719) patients were enrolled in this trial and randomized following transplantation; 284 were randomized to receive Rapamune Oral Solution 2 mg/day; 274 were randomized to receive Rapamune Oral Solution 5 mg/day, and 161 to receive azathioprine 2-3 mg/kg/day. Study 2 was conducted in Australia, Canada, Europe, and the United States, at a total of 34 sites. Five hundred seventy-six (576) patients were enrolled in this trial and randomized before transplantation; 227 were randomized to receive Rapamune Oral Solution 2 mg/day; 219 were randomized to receive Rapamune Oral Solution 5 mg/day, and 130 to receive placebo. In both studies, the use of antilymphocyte antibody induction therapy was prohibited. In both studies, the primary efficacy endpoint was the rate of efficacy failure in the first 6 months after transplantation. Efficacy failure was defined as the first occurrence of an acute rejection episode (confirmed by biopsy), graft loss, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>The <a href="#id_2bba511d-81b1-4e0e-ba2f-04fb2bb16d77">tables</a> below summarize the results of the primary efficacy analyses from these trials. Rapamune Oral Solution, at doses of 2 mg/day and 5 mg/day, significantly reduced the incidence of efficacy failure (statistically significant at the&lt; 0.025 level; nominal significance level adjusted for multiple [2] dose comparisons) at 6 months following transplantation compared with both azathioprine and placebo. </p>
<a name="id_2bba511d-81b1-4e0e-ba2f-04fb2bb16d77"></a><table width="430.000">
<caption><span>INCIDENCE (%) OF EFFICACY FAILURE AT 6 AND 24 MONTHS FOR STUDY 1<span class="Sup">a,b</span></span></caption>
<col align="left" width="53.5%">
<col align="left" width="15.1%">
<col align="left" width="15.1%">
<col align="left" width="16.3%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Parameter </td>
<td class="Botrule" align="center" valign="top">Rapamune <br>Oral Solution<br>2 mg/day<br>(n = 284) </td>
<td class="Botrule" align="center" valign="top">Rapamune <br>Oral Solution<br>5 mg/day<br>(n = 274) </td>
<td class="Botrule" align="center" valign="top">Azathioprine<br>2-3 mg/kg/day<br>(n = 161) </td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids. <br>b: Includes patients who prematurely discontinued treatment. <br>c: Primary endpoint. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold">Efficacy failure at 6 months<span class="Sup">c</span></span></td>
<td class="Toprule" align="center" valign="top">18.7</td>
<td class="Toprule" align="center" valign="top">16.8</td>
<td align="center" valign="top">32.3</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Components of efficacy failure </span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Biopsy-proven acute rejection</td>
<td align="center" valign="top">16.5</td>
<td align="center" valign="top">11.3</td>
<td align="center" valign="top">29.2</td>
</tr>
<tr>
<td align="left" valign="top">     Graft loss</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">2.9</td>
<td align="center" valign="top">2.5</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center" valign="top">0.7</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">     Lost to follow-up</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">0.7</td>
<td align="center" valign="top">0.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Efficacy failure at 24 months</span></td>
<td align="center" valign="top">32.8</td>
<td align="center" valign="top">25.9</td>
<td align="center" valign="top">36.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Components of efficacy failure </span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Biopsy-proven acute rejection</td>
<td align="center" valign="top">23.6</td>
<td align="center" valign="top">17.5</td>
<td align="center" valign="top">32.3</td>
</tr>
<tr>
<td align="left" valign="top">     Graft loss</td>
<td align="center" valign="top">3.9</td>
<td align="center" valign="top">4.7</td>
<td align="center" valign="top">3.1</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center" valign="top">4.2</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Lost to follow-up</td>
<td class="Botrule" align="center" valign="top">1.1</td>
<td class="Botrule" align="center" valign="top">0.4</td>
<td class="Botrule" align="center" valign="top">0.6</td>
</tr>
</tbody>
</table>
<a name="id_2464befa-3513-4833-a3a7-c6ea3bcb9eac"></a><table width="429.000">
<caption><span>INCIDENCE (%) OF EFFICACY FAILURE AT 6 AND 36 MONTHS FOR STUDY 2<span class="Sup">a,b</span></span></caption>
<col align="left" width="56.4%">
<col align="left" width="15.9%">
<col align="left" width="15.9%">
<col align="left" width="11.9%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Parameter </td>
<td class="Botrule" align="center" valign="top">Rapamune <br>Oral Solution<br>2 mg/day<br>(n = 227) </td>
<td class="Botrule" align="center" valign="top">Rapamune<br>Oral Solution<br>5 mg/day<br>(n = 219) </td>
<td class="Botrule" align="center" valign="top">Placebo<br>(n = 130) </td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids. <br>b: Includes patients who prematurely discontinued treatment. <br>c: Primary endpoint. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold">Efficacy failure at 6 months<span class="Sup">c</span></span></td>
<td class="Toprule" align="center" valign="top">30.0</td>
<td class="Toprule" align="center" valign="top">25.6</td>
<td align="center" valign="top">47.7</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Components of efficacy failure </span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Biopsy-proven acute rejection</td>
<td align="center" valign="top">24.7</td>
<td align="center" valign="top">19.2</td>
<td align="center" valign="top">41.5</td>
</tr>
<tr>
<td align="left" valign="top">     Graft loss</td>
<td align="center" valign="top">3.1</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">3.9</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">2.3</td>
</tr>
<tr>
<td align="left" valign="top">     Lost to follow-up</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Efficacy failure at 36 months</span></td>
<td align="center" valign="top">44.1</td>
<td align="center" valign="top">41.6</td>
<td align="center" valign="top">54.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Components of efficacy failure </span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Biopsy-proven acute rejection</td>
<td align="center" valign="top">32.2</td>
<td align="center" valign="top">27.4</td>
<td align="center" valign="top">43.9</td>
</tr>
<tr>
<td align="left" valign="top">     Graft loss</td>
<td align="center" valign="top">6.2</td>
<td align="center" valign="top">7.3</td>
<td align="center" valign="top">4.6</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center" valign="top">5.7</td>
<td align="center" valign="top">5.9</td>
<td align="center" valign="top">5.4</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Lost to follow-up</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0.9</td>
<td class="Botrule" align="center" valign="top">0.8</td>
</tr>
</tbody>
</table>
<p>Patient and graft survival at 1 year were co-primary endpoints. The following <a href="#id_1162ee48-dc12-41ee-8ac5-6c2ebaaa8c86">table</a> shows graft and patient survival at 1 and 2 years in Study 1, and 1 and 3 years in Study 2. The graft and patient survival rates were similar in patients treated with Rapamune and comparator-treated patients. </p>
<a name="id_1162ee48-dc12-41ee-8ac5-6c2ebaaa8c86"></a><table width="429.000">
<caption><span>GRAFT AND PATIENT SURVIVAL (%) FOR STUDY 1 (12 AND 24 MONTHS) AND STUDY 2 (12 AND 36 MONTHS)<span class="Sup">a,b</span></span></caption>
<col align="left" width="32.9%">
<col align="left" width="16.8%">
<col align="left" width="16.8%">
<col align="left" width="18.6%">
<col align="left" width="14.9%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">     Parameter </td>
<td class="Botrule" align="center" valign="top">Rapamune<br>Oral Solution<br>2 mg/day </td>
<td class="Botrule" align="center" valign="top">Rapamune<br>Oral Solution<br>5 mg/day </td>
<td class="Botrule" align="center" valign="top">Azathioprine<br>2-3 mg/kg/day </td>
<td class="Botrule" align="center" valign="top">Placebo </td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids. <br>b: Includes patients who prematurely discontinued treatment. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Study 1</td>
<td class="Botrule" align="center" valign="top">(n = 284)</td>
<td class="Botrule" align="center" valign="top">(n = 274)</td>
<td class="Botrule" align="center" valign="top">(n = 161)</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Graft survival</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 12</td>
<td align="center" valign="top">94.7</td>
<td align="center" valign="top">92.7</td>
<td align="center" valign="top">93.8</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 24</td>
<td align="center" valign="top">85.2</td>
<td align="center" valign="top">89.1</td>
<td align="center" valign="top">90.1</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Patient survival</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 12</td>
<td align="center" valign="top">97.2</td>
<td align="center" valign="top">96.0</td>
<td align="center" valign="top">98.1</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">     Month 24</td>
<td class="Botrule" align="center" valign="top">92.6</td>
<td class="Botrule" align="center" valign="top">94.9</td>
<td class="Botrule" align="center" valign="top">96.3</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Study 2</td>
<td class="Botrule" align="center" valign="top">(n = 227)</td>
<td class="Botrule" align="center" valign="top">(n = 219)</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">(n = 130)</td>
</tr>
<tr>
<td align="left" valign="top">Graft survival</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 12</td>
<td align="center" valign="top">89.9</td>
<td align="center" valign="top">90.9</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">87.7</td>
</tr>
<tr>
<td align="left" valign="top">     Month 36</td>
<td align="center" valign="top">81.1</td>
<td align="center" valign="top">79.9</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">80.8</td>
</tr>
<tr>
<td align="left" valign="top">Patient survival</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 12</td>
<td align="center" valign="top">96.5</td>
<td align="center" valign="top">95.0</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">94.6</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Month 36</td>
<td class="Botrule" align="center" valign="top">90.3</td>
<td class="Botrule" align="center" valign="top">89.5</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">90.8</td>
</tr>
</tbody>
</table>
<p>The reduction in the incidence of first biopsy-confirmed acute rejection episodes in patients treated with Rapamune compared with the control groups included a reduction in all grades of rejection. </p>
<p>In Study 1, which was prospectively stratified by race within center, efficacy failure was similar for Rapamune Oral Solution 2 mg/day and lower for Rapamune Oral Solution 5 mg/day compared with azathioprine in Black patients. In Study 2, which was not prospectively stratified by race, efficacy failure was similar for both Rapamune Oral Solution doses compared with placebo in Black patients. The decision to use the higher dose of Rapamune Oral Solution in Black patients must be weighed against the increased risk of dose-dependent adverse events that were observed with the Rapamune Oral Solution 5-mg dose [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_040fcef0-726c-4184-8408-6a5729e48ee9">6.1</a>)</span>]. </p>
<a name="id_b7d91b39-8712-4aae-a1fa-42bdb707b3ba"></a><table width="416.000">
<caption><span>PERCENTAGE OF EFFICACY FAILURE BY RACE AT 6 MONTHS<span class="Sup">a,b</span></span></caption>
<col align="left" width="26.9%">
<col align="left" width="18.5%">
<col align="left" width="17.5%">
<col align="left" width="18.5%">
<col align="left" width="18.5%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">     Parameter</td>
<td class="Botrule" align="center" valign="top">Rapamune<br>Oral Solution<br>2 mg/day</td>
<td class="Botrule" align="center" valign="top">Rapamune<br>Oral Solution<br>5 mg/day</td>
<td class="Botrule" align="center" valign="top">Azathioprine<br>2-3 mg/kg/day</td>
<td class="Botrule" align="center" valign="top">Placebo</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top"><p class="First">a: Patients received cyclosporine and corticosteroids. <br>b: Includes patients who prematurely discontinued treatment. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Study 1</td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Black (n = 166)</td>
<td align="center" valign="top">34.9 (n = 63)</td>
<td align="center" valign="top">18.0 (n = 61)</td>
<td align="center" valign="top">33.3 (n = 42)</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">     Non-Black (n = 553)</td>
<td class="Botrule" align="center" valign="top">14.0 (n = 221)</td>
<td class="Botrule" align="center" valign="top">16.4 (n = 213)</td>
<td class="Botrule" align="center" valign="top">31.9 (n = 119)</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Study 2</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Black (n = 66)</td>
<td align="center" valign="top">30.8 (n = 26)</td>
<td align="center" valign="top">33.7 (n = 27)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">38.5 (n = 13)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Non-Black (n = 510)</td>
<td class="Botrule" align="center" valign="top">29.9 (n = 201)</td>
<td class="Botrule" align="center" valign="top">24.5 (n = 192)</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">48.7 (n = 117)</td>
</tr>
</tbody>
</table>
<p>Mean glomerular filtration rates (GFR) post-transplant were calculated by using the Nankivell equation at 12 and 24 months for Study 1, and 12 and 36 months for Study 2. Mean GFR was lower in patients treated with cyclosporine and Rapamune Oral Solution compared with those treated with cyclosporine and the respective azathioprine or placebo control. </p>
<a name="id_ef015d39-ee1e-475b-8bbc-21b0aba2fc26"></a><table width="430.000">
<caption><span>OVERALL CALCULATED GLOMERULAR FILTRATION RATES (Mean ± SEM, cc/min) BY NANKIVELL EQUATION POST‑TRANSPLANT<span class="Sup">a,b</span></span></caption>
<col align="left" width="25.6%">
<col align="left" width="18.6%">
<col align="left" width="18.6%">
<col align="left" width="18.6%">
<col align="left" width="18.6%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Parameter</td>
<td class="Botrule" align="center" valign="bottom">Rapamune<br>Oral Solution<br>2 mg/day</td>
<td class="Botrule" align="center" valign="bottom">Rapamune<br>Oral Solution<br>5 mg/day</td>
<td class="Botrule" align="center" valign="top">Azathioprine<br>2-3 mg/kg/day</td>
<td class="Botrule" align="center" valign="top">Placebo</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top"><p class="First">a: Includes patients who prematurely discontinued treatment. <br>b: Patients who had a graft loss were included in the analysis with GFR set to 0.0. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Study 1</td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 12</td>
<td align="center" valign="top">57.4 ± 1.3<br>(n = 269)</td>
<td align="center" valign="top">54.6 ± 1.3<br>(n = 248)</td>
<td align="center" valign="top">64.1 ± 1.6)<br>(n = 149)</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">     Month 24</td>
<td class="Botrule" align="center" valign="top">58.4 ± 1.5<br>(n = 221)</td>
<td class="Botrule" align="center" valign="top">52.6 ± 1.5<br>(n = 222)</td>
<td class="Botrule" align="center" valign="top">62.4 ± 1.9<br>(n = 132)</td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Study 2</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Month 12</td>
<td align="center" valign="top">52.4 ± 1.5<br>(n = 211)</td>
<td align="center" valign="top">51.5 ± 1.5<br>(n = 199)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">58.0 ± 2.1<br>(n = 117)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Month 36</td>
<td class="Botrule" align="center" valign="top">48.1 ± 1.8<br>(n = 183)</td>
<td class="Botrule" align="center" valign="top">46.1 ± 2.0<br>(n = 177)</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">53.4 ± 2.7<br>(n = 102)</td>
</tr>
</tbody>
</table>
<p>Within each treatment group in Studies 1 and 2, mean GFR at one-year post-transplant was lower in patients who experienced at least one episode of biopsy-proven acute rejection, compared with those who did not. </p>
<p>Renal function should be monitored, and appropriate adjustment of the immunosuppressive regimen should be considered in patients with elevated or increasing serum creatinine levels [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_c370c161-867e-4b26-9b49-e961de43442e">5.8</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60ba7529-bc66-4f48-b764-4d363967895c"></a><a name="section-13.1.2"></a><p></p>
<h3><span class="Underline"><span class="Italics">Rapamune Tablets</span></span></h3>
<p class="First">The safety and efficacy of Rapamune Oral Solution and Rapamune Tablets for the prevention of organ rejection following renal transplantation were demonstrated to be clinically equivalent in a randomized, multicenter, controlled trial [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b45e0a86-53f4-4e2f-9b44-442a9c290363"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Cyclosporine Withdrawal Study </h2>
<p class="First">The safety and efficacy of Rapamune as a maintenance regimen were assessed following cyclosporine withdrawal at 3 to 4 months after renal transplantation. Study 3 was a randomized, multicenter, controlled trial conducted at 57 centers in Australia, Canada, and Europe. Five hundred twenty-five (525) patients were enrolled. All patients in this study received the tablet formulation. This study compared patients who were administered Rapamune, cyclosporine, and corticosteroids continuously with patients who received this same standardized therapy for the first 3 months after transplantation (pre-randomization period) followed by the withdrawal of cyclosporine. During cyclosporine withdrawal, the Rapamune dosages were adjusted to achieve targeted sirolimus whole blood trough concentration ranges (16 to 24 ng/mL until month 12, then 12 to 20 ng/mL thereafter, expressed as chromatographic assay values). At 3 months, 430 patients were equally randomized to either continue Rapamune with cyclosporine therapy or to receive Rapamune as a maintenance regimen following cyclosporine withdrawal. </p>
<p>Eligibility for randomization included no Banff Grade 3 acute rejection or vascular rejection episode in the 4 weeks before random assignment, serum creatinine ≤ 4.5 mg/dL, and adequate renal function to support cyclosporine withdrawal (in the opinion of the investigator). The primary efficacy endpoint was graft survival at 12 months after transplantation. Secondary efficacy endpoints were the rate of biopsy-confirmed acute rejection, patient survival, incidence of efficacy failure (defined as the first occurrence of either biopsy-proven acute rejection, graft loss, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), and treatment failure (defined as the first occurrence of either discontinuation, acute rejection, graft loss, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>). </p>
<p>The following <a href="#id_930ca1d2-2c2b-4a8a-80c6-c5035ae1b4b1">table</a> summarizes the resulting graft and patient survival at 12, 24, and 36 months for this trial. At 12, 24, and 36 months, graft and patient survival were similar for both groups. </p>
<a name="id_930ca1d2-2c2b-4a8a-80c6-c5035ae1b4b1"></a><table width="429.000">
<caption><span>GRAFT AND PATIENT SURVIVAL (%): STUDY 3<span class="Sup">a</span></span></caption>
<col align="left" width="33.3%">
<col align="left" width="33.3%">
<col align="left" width="33.3%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Parameter </td>
<td class="Botrule" align="center" valign="bottom">Rapamune with<br>Cyclosporine Therapy<br>(n = 215) </td>
<td class="Botrule" align="center" valign="bottom">Rapamune Following Cyclosporine<br>Withdrawal<br>(n = 215) </td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top"><p class="First">a: Includes patients who prematurely discontinued treatment. <br>b: Primary efficacy endpoint. <br>c: Survival including loss to follow-up as an event.<br>d: Initial planned duration of the study. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Graft Survival</td>
<td class="Toprule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Month 12<span class="Sup">b</span>
</td>
<td align="center" valign="top">95.3<span class="Sup">c</span>
</td>
<td align="center" valign="top">97.2</td>
</tr>
<tr>
<td align="left" valign="top">Month 24</td>
<td align="center" valign="top">91.6</td>
<td align="center" valign="top">94.0</td>
</tr>
<tr>
<td align="left" valign="top">Month 36<span class="Sup">d</span>
</td>
<td align="center" valign="top">87.0</td>
<td align="center" valign="top">91.6</td>
</tr>
<tr>
<td align="left" valign="top">
<br>Patient Survival</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Month 12</td>
<td align="center" valign="top">97.2</td>
<td align="center" valign="top">98.1</td>
</tr>
<tr>
<td align="left" valign="top">Month 24</td>
<td align="center" valign="top">94.4</td>
<td align="center" valign="top">95.8</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Month 36<span class="Sup">d</span>
</td>
<td class="Botrule" align="center" valign="top">91.6</td>
<td class="Botrule" align="center" valign="top">94.0</td>
</tr>
</tbody>
</table>
<p>The following <a href="#id_0a80b134-2f8c-4d15-b674-2efbb43952c8">table</a> summarizes the results of first biopsy-proven acute rejection at 12 and 36 months. There was a significant difference in first biopsy-proven rejection rates between the two groups after randomization and through 12 months. Most of the post-randomization acute rejections occurred in the first 3 months following randomization. </p>
<a name="id_0a80b134-2f8c-4d15-b674-2efbb43952c8"></a><table width="430.000">
<caption><span>INCIDENCE OF FIRST BIOPSY-PROVEN ACUTE REJECTION (%) BY TREATMENT GROUP AT 36 MONTHS: STUDY 3<span class="Sup">a,b</span></span></caption>
<col align="left" width="46.5%">
<col align="left" width="26.7%">
<col align="left" width="26.7%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Period</td>
<td class="Botrule" align="center" valign="bottom">Rapamune with Cyclosporine Therapy<br>(n = 215)</td>
<td class="Botrule" align="center" valign="bottom">Rapamune Following Cyclosporine Withdrawal<br>(n = 215)</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top"><p class="First">a: Includes patients who prematurely discontinued treatment. <br>b: All patients received corticosteroids. <br>c: Randomization occurred at 3 months ± 2 weeks.</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Pre-randomization<span class="Sup">c</span>
</td>
<td class="Toprule" align="center" valign="top">9.3</td>
<td align="center" valign="top">10.2</td>
</tr>
<tr>
<td align="left" valign="top">Post-randomization through 12 months<span class="Sup">c</span>
</td>
<td align="center" valign="top">4.2</td>
<td align="center" valign="top">9.8</td>
</tr>
<tr>
<td align="left" valign="top">Post-randomization from 12 to 36 months</td>
<td align="center" valign="top">1.4</td>
<td align="center" valign="top">0.5</td>
</tr>
<tr>
<td align="left" valign="top">Post-randomization through 36 months</td>
<td align="center" valign="top">5.6</td>
<td align="center" valign="top">10.2</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Total at 36 months</td>
<td class="Botrule" align="center" valign="top">14.9</td>
<td class="Botrule" align="center" valign="top">20.5</td>
</tr>
</tbody>
</table>
<p>Patients receiving renal allografts with ≥ 4 HLA mismatches experienced significantly higher rates of acute rejection following randomization to the cyclosporine withdrawal group, compared with patients who continued cyclosporine (15.3% vs. 3.0%). Patients receiving renal allografts with ≤ 3 HLA mismatches demonstrated similar rates of acute rejection between treatment groups (6.8% vs. 7.7%) following randomization. </p>
<p>The following <a href="#id_d223d9ca-51c1-4f42-a729-ea265622e4a4">table</a> summarizes the mean calculated GFR in Study 3 (cyclosporine withdrawal study). </p>
<a name="id_d223d9ca-51c1-4f42-a729-ea265622e4a4"></a><table width="429.000">
<caption><span>CALCULATED GLOMERULAR FILTRATION RATES (mL/min) BY NANKIVELL EQUATION AT 12, 24, AND 36 MONTHS POST-TRANSPLANT: STUDY 3<span class="Sup">a,b,c</span></span></caption>
<col align="left" width="33.3%">
<col align="left" width="33.3%">
<col align="left" width="33.3%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">Parameter</td>
<td class="Botrule" align="center" valign="top">Rapamune with<br>Cyclosporine Therapy</td>
<td class="Botrule" align="center" valign="top">Rapamune Following Cyclosporine Withdrawal</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top"><p class="First">a: Includes patients who prematurely discontinued treatment. <br>b: Patients who had a graft loss were included in the analysis and had their GFR set to 0.0. <br>c: All patients received corticosteroids. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Month 12</td>
<td class="Toprule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Mean ± SEM</td>
<td align="center" valign="top">53.2 ± 1.5<br>(n = 208)</td>
<td align="center" valign="top">59.3 ± 1.5<br>(n = 203)</td>
</tr>
<tr>
<td align="left" valign="top">Month 24</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">     Mean ± SEM</td>
<td align="center" valign="top">48.4 ± 1.7<br>(n = 203)</td>
<td align="center" valign="top">58.4 ± 1.6<br>(n = 201)</td>
</tr>
<tr>
<td align="left" valign="top">Month 36</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Mean± SEM</td>
<td class="Botrule" align="center" valign="top">47.0 ± 1.8<br>(n = 196)</td>
<td class="Botrule" align="center" valign="top">58.5 ± 1.9<br>(n = 199)</td>
</tr>
</tbody>
</table>
<p>The mean GFR at 12, 24, and 36 months, calculated by the Nankivell equation, was significantly higher for patients receiving Rapamune as a maintenance regimen following cyclosporine withdrawal than for those in the Rapamune with cyclosporine therapy group. Patients who had an acute rejection prior to randomization had a significantly higher GFR following cyclosporine withdrawal compared to those in the Rapamune with cyclosporine group. There was no significant difference in GFR between groups for patients who experienced acute rejection post-randomization. </p>
<p>Although the initial protocol was designed for 36 months, there was a subsequent amendment to extend this study. The results for the cyclosporine withdrawal group at months 48 and 60 were consistent with the results at month 36. Fifty-two percent (112/215) of the patients in the Rapamune with cyclosporine withdrawal group remained on therapy to month 60 and showed sustained GFR. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_84a817be-e3ad-4544-88f6-3758a95edd14"></a><a name="section-13.3"></a><p></p>
<h2>14.3 High-Immunologic Risk Patients </h2>
<p class="First">Rapamune was studied in a one-year, clinical trial in high risk patients (Study 4) who were defined as Black transplant recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reasons and/or patients with high panel-reactive antibodies (PRA; peak PRA level &gt; 80%). Patients received concentration-controlled sirolimus and cyclosporine (MODIFIED), and corticosteroids per local practice. The Rapamune dose was adjusted to achieve target whole blood trough sirolimus concentrationsof 10-15 ng/mL (chromatographic method) throughout the 12-month study period. The cyclosporine dose was adjusted to achieve target whole blood trough concentrations of 200-300 ng/mL through week 2, 150-200 ng/mL from week 2 to week 26, and 100-150 ng/mL from week 26 to week 52 [see <span class="Italics">Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_93eeaed8-03da-4fd3-b001-b9234a2acc79">12.3</a>)</span>] for the observed trough concentrations ranges. Antibody induction was allowed per protocol as prospectively defined at each transplant center, and was used in 88.4% of patients. The study was conducted at 35 centers in the United States. A total of 224 patients received a transplant and at least one dose of sirolimus and cyclosporine and was comprised of 77.2% Black patients, 24.1% repeat renal transplant recipients, and 13.5% patients with high PRA. Efficacy was assessed with the following endpoints, measured at 12 months: efficacy failure (defined as the first occurrence of biopsy-confirmed acute rejection, graft loss, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), first occurrence of graft loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and renal function as measured by the calculated GFR using the Nankivell formula. The <a href="#id_e4f07962-e7dd-4b0b-862f-f75a9580d574">table</a> below summarizes the result of these endpoints. </p>
<a name="id_e4f07962-e7dd-4b0b-862f-f75a9580d574"></a><table width="430.000">
<caption><span>EFFICACY FAILURE, GRAFT LOSS OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> AND CALCULATED GLOMERULAR FUNCTION RATES (mL/min) BY NANKIVELL EQUATION AT 12 MONTHS POST-TRANSPLANT: STUDY 4 </span></caption>
<col align="left" width="41.2%">
<col align="left" width="58.8%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="bottom">     Parameter</td>
<td class="Botrule" align="center" valign="top">Rapamune<br>with Cyclosporine, Corticosteroids<br>(n = 224)</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="2" valign="top"><p class="First">a: Calculated glomerular filtration rate by Nankivell equation. <br>b: Patients who had graft loss were included in this analysis with GFR set to 0. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle">Efficacy Failure (%)</td>
<td align="center" valign="middle">23.2</td>
</tr>
<tr>
<td align="left" valign="middle">Graft Loss or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (%)</td>
<td align="center" valign="middle">9.8</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Renal Function (mean± SEM)<span class="Sup">a,b</span>
</td>
<td class="Botrule" align="center" valign="middle">52.6 ± 1.6 <br>(n = 222)</td>
</tr>
</tbody>
</table>
<p>Patient survival at 12 months was 94.6%. The incidence of biopsy-confirmed acute rejection was 17.4% and the majority of the episodes of acute rejection were mild in severity. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b21560b-a9b0-4fac-99a3-2fe516c6bc25"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Conversion from Calcineurin Inhibitors to Rapamune in Maintenance Renal Transplant Patients </h2>
<p class="First">Conversion from calcineurin inhibitors (CNI) to Rapamune was assessed in maintenance renal transplant patients 6 months to 10 years post‑transplant (Study 5). This study was a randomized, multicenter, controlled trial conducted at 111 centers globally, including US and Europe, and was intended to show that renal function was improved by conversion from CNI to Rapamune. Eight hundred thirty (830) patients were enrolled and stratified by baseline calculated glomerular filtration rate (GFR, 20-40 mL/min vs. greater than 40 mL/min). In this trial there was no benefit associated with conversion with regard to improvement in renal function and a greater incidence of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the Rapamune conversion arm. In addition, enrollment of patients with baseline calculated GFR less than 40 mL/min was discontinued due to a higher rate of serious adverse events, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, acute rejection, graft loss and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [see <span class="Italics">Adverse Reactions (<a href="#i4i_section_id_f5f8cfd9-646a-4928-a7ce-2bad0daaf4e8">6.4</a>)</span>].</p>
<p>This study compared renal transplant patients (6-120 months after transplantation) who were converted from calcineurin inhibitors to Rapamune, with patients who continued to receive calcineurin inhibitors. Concomitant immunosuppressive medications included mycophenolate mofetil (MMF), azathioprine (AZA), and corticosteroids. Rapamune was initiated with a single loading dose of 12-20 mg, after which dosing was adjusted to achieve a target sirolimus whole blood trough concentration of 8-20 ng/mL (chromatographic method). The efficacy endpoint was calculated GFR at 12 months post-randomization. Additional endpoints included biopsy-confirmed acute rejection, graft loss, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Findings in the patient stratum with baseline calculated GFR greater than 40 mL/min (Rapamune conversion, n = 497; CNI continuation, n = 246) are summarized <a href="#id_5cd3b950-2a49-4eae-a815-37957d94b308">below</a>: There was no clinically or statistically significant improvement in Nankivell GFR compared to baseline. </p>
<a name="id_5cd3b950-2a49-4eae-a815-37957d94b308"></a><table width="432.000">
<caption><span>RENAL FUNCTION IN STABLE RENAL TRANSPLANT PATIENTS IN PATIENTS WITH BASELINE GFR &gt; 40 mL/min THE RAPAMUNE CONVERSION STUDY (STUDY 5) </span></caption>
<col align="left" width="25.0%">
<col align="left" width="25.0%">
<col align="left" width="25.0%">
<col align="left" width="25.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Parameter</td>
<td class="Rrule" align="center" valign="top">Rapamune conversion<br>N=496</td>
<td class="Rrule" align="center" valign="top">CNI continuation<br>N=245</td>
<td class="Botrule Rrule" align="center" valign="top">Difference (95% CI)</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">GFR mL/min (Nankivell) at 1 year</td>
<td class="Botrule Rrule" align="center" valign="top">59.0</td>
<td class="Botrule Rrule" align="center" valign="top">57.7</td>
<td class="Botrule Rrule" align="center" valign="top">1.3 (-1.1, 3.7)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">GFR mL/min (Nankivell) at 2 year</td>
<td class="Rrule" align="center" valign="top">53.7</td>
<td class="Rrule" align="center" valign="top">52.1</td>
<td class="Botrule Rrule" align="center" valign="top">1.6 (-1.4, 4.6)</td>
</tr>
</tbody>
</table>
<p>The rates of acute rejection, graft loss, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were similar at 1 and 2 years. Treatment-emergent adverse events occurred more frequently during the first 6 months after Rapamune conversion. The rates of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were significantly higher for the sirolimus conversion group. </p>
<p>While the mean and median values for urinary protein to creatinine ratio were similar between treatment groups at baseline, significantly higher mean and median levels of urinary protein excretion were seen in the Rapamune conversion arm at 1 year and at 2 years, as shown in the <a href="#id_4e2497ec-e4c0-4239-beeb-c6cab89c76be">table</a> below [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_2318149a-ec06-482a-b5ee-745dcef84ad8">5.9</a>)</span>]. In addition, when compared to patients who continued to receive calcineurin inhibitors, a higher percentage of patients had urinary protein to creatinine ratios &gt; 1 at 1 and 2 years after sirolimus conversion. This difference was seen in both patients who had a urinary protein to creatinine ratio ≤ 1 and those who had a protein to creatinine ratio &gt; 1 at baseline. More patients in the sirolimus conversion group developed nephrotic range <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, as defined by a urinary protein to creatinine ratio &gt; 3.5 (46/482 [9.5%] vs. 9/239 [3.8%]), even when the patients with baseline nephrotic range <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> were excluded. The rate of nephrotic range <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> was significantly higher in the sirolimus conversion group compared to the calcineurin inhibitor continuation group with baseline urinary protein to creatinine ratio &gt; 1 (13/29 vs. 1/14), excluding patients with baseline nephrotic range <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. </p>
<a name="id_4e2497ec-e4c0-4239-beeb-c6cab89c76be"></a><table width="431.000">
<caption><span>MEAN AND MEDIAN VALUES FOR URINARY PROTEIN TO CREATININE RATIO (mg/mg) BETWEEN TREATMENT GROUPS AT BASELINE, 1 AND 2 YEARS IN THE STRATUM WITH BASELINE CALCULATED GFR &gt; 40 mL/min </span></caption>
<col align="left" width="12.5%">
<col align="left" width="12.3%">
<col align="left" width="13.0%">
<col align="left" width="12.3%">
<col align="left" width="12.3%">
<col align="left" width="13.0%">
<col align="left" width="12.3%">
<col align="left" width="12.3%">
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Study period</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><span class="Bold">Sirolimus Conversion</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">CNI Continuation</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Mean ± SD</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Median</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Mean ± SD</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Median</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Baseline</td>
<td class="Botrule Rrule" align="center" valign="top">410</td>
<td class="Botrule Rrule" align="center" valign="top">0.35 ± 0.76</td>
<td class="Botrule Rrule" align="center" valign="top">0.13</td>
<td class="Botrule Rrule" align="center" valign="top">207</td>
<td class="Botrule Rrule" align="center" valign="top">0.28 ± 0.61</td>
<td class="Botrule Rrule" align="center" valign="top">0.11</td>
<td class="Botrule Rrule" align="center" valign="top">0.381</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">1 year</td>
<td class="Botrule Rrule" align="center" valign="top">423</td>
<td class="Botrule Rrule" align="center" valign="top">0.88 ± 1.61</td>
<td class="Botrule Rrule" align="center" valign="top">0.31</td>
<td class="Botrule Rrule" align="center" valign="top">203</td>
<td class="Botrule Rrule" align="center" valign="top">0.37 ± 0.88</td>
<td class="Botrule Rrule" align="center" valign="top">0.14</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">2 years</td>
<td class="Rrule" align="center" valign="top">373</td>
<td class="Rrule" align="center" valign="top">0.86 ± 1.48</td>
<td class="Rrule" align="center" valign="top">0.32</td>
<td class="Rrule" align="center" valign="top">190</td>
<td class="Rrule" align="center" valign="top">0.47 ± 0.98</td>
<td class="Rrule" align="center" valign="top">0.13</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;0.001</td>
</tr>
</tbody>
</table>
<p>The above information should be taken into account when considering conversion from calcineurin inhibitors to Rapamune in stable renal transplant patients due to the lack of evidence showing that renal function improves following conversion, and the finding of a greater increment in urinary protein excretion, and an increased incidence of treatment-emergent nephrotic range <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> following conversion to Rapamune. This was particularly true among patients with existing abnormal urinary protein excretion prior to conversion. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f02c26f-b0c0-4ff6-911e-9a8d569ea51f"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Pediatrics </h2>
<p class="First">Rapamune was evaluated in a 36-month, open-label, randomized, controlled clinical trial at 14 North American centers in pediatric (aged 3 to &lt; 18 years) renal transplant patients considered to be at high-immunologic risk for developing <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span>, defined as a history of one or more <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span> episodes and/or the presence of <span class="product-label-link" type="condition" conceptid="4032423" conceptname="Transplant glomerulopathy">chronic allograft nephropathy</span> on a renal biopsy. Seventy-eight (78) subjects were randomized in a 2:1 ratio to Rapamune (sirolimus target concentrations of 5 to 15 ng/mL, by chromatographic assay, n = 53) in combination with a calcineurin inhibitor and corticosteroids or to continue calcineurin-inhibitor-based immunosuppressive therapy (n = 25). The primary endpoint of the study was efficacy failure as defined by the first occurrence of biopsy-confirmed acute rejection, graft loss, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and the trial was designed to show superiority of Rapamune added to a calcineurin-inhibitor-based immunosuppressive regimen compared to a calcineurin-inhibitor-based regimen. The cumulative incidence of efficacy failure up to 36 months was 45.3% in the Rapamune group compared to 44.0% in the control group, and did not demonstrate superiority. There was one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in each group. The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>), and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_c370c161-867e-4b26-9b49-e961de43442e">5.8</a>)</span>]. This study does not support the addition of Rapamune to calcineurin-inhibitor-based immunosuppressive therapy in this subpopulation of pediatric renal transplant patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_e7f73d40-1a4a-4d0b-86ab-7d1f95b0550a"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First"><span class="Italics">Clinical Therapeutics,</span> Volume 22, Supplement B, April 2000 [see <span class="Italics">Dosage and Administration</span><span class="Italics"> (<a href="#i4i_section_id_80a85758-b896-4e95-8e23-e8220da17166">2.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_4856e500-05db-449c-9d48-f76ed4890cdb"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Since Rapamune is not absorbed through the skin, there are no special precautions. However, if direct contact with the skin or mucous membranes occurs, wash thoroughly with soap and water; rinse eyes with plain water. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_134e2756-8bed-4088-bc84-d5c94b9b0099"></a><a name="section-15.1"></a><p></p>
<h2>16.1 Rapamune Oral Solution </h2>
<p class="First">Each Rapamune Oral Solution carton, NDC 0008-1030-06, contains one 2 oz (60 mL fill) amber glass bottle of sirolimus (concentration of 1 mg/mL), one oral syringe adapter for fitting into the neck of the bottle, sufficient disposable amber oral syringes and caps for daily dosing, and a carrying case. </p>
<p>Rapamune Oral Solution bottles should be stored protected from light and refrigerated at 2°C to 8°C (36°F to 46°F). Once the bottle is opened, the contents should be used within one month. If necessary, the patient may store the bottles at room temperatures up to 25°C (77°F) for a short period of time (e.g., not more than 15 days for the bottles). </p>
<p>An amber syringe and cap are provided for dosing, and the product may be kept in the syringe for a maximum of 24 hours at room temperatures up to 25°C (77°F) or refrigerated at 2°C to 8°C (36°F to 46°F). The syringe should be discarded after one use. After dilution, the preparation should be used immediately. </p>
<p>Rapamune Oral Solution provided in bottles may develop a slight haze when refrigerated. If such a haze occurs, allow the product to stand at room temperature and shake gently until the haze disappears. The presence of this haze does not affect the quality of the product. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a171131-7bcb-47e0-84d9-686e7c935ce5"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Rapamune Tablets </h2>
<p class="First">Rapamune Tablets are available as follows: </p>
<ul>
<li>NDC 0008-1041-05, 1 mg, white, triangular-shaped tablets marked“RAPAMUNE 1 mg? on one side; bottle containing 100 tablets. </li>
<li>NDC 0008-1041-10, 1 mg, white, triangular-shaped tablets marked“RAPAMUNE 1 mg? on one side; in Redipak<span class="Sup">®</span> cartons of 100 tablets (10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 10 tablets each). </li>
<li>NDC 0008-1042-05, 2 mg, yellow-to-beige triangular-shaped tablets marked “RAPAMUNE 2 mg? on one side; bottle containing 100 tablets. </li>
</ul>
<p>Rapamune Tablets should be stored at 20° to 25°C [USP Controlled Room Temperature] (68° to 77°F). Use cartons to protect <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards and strips from light. Dispense in a tight, light-resistant container as defined in the USP. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ea112a7b-8d8b-4559-81aa-0500c69c7565"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling <span class="Italics"> (<a href="#i4i_section_id_9ce681e3-d3a4-4ebb-b164-b9082bb4ca3a">17.4</a>)</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_509b017e-ebb1-4224-967a-a108f9f936ea"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Dosage </h2>
<p class="First">Patients should be given complete dosage instructions [see <span class="Italics">Patient Counseling Information</span><span class="Italics"> (<a href="#i4i_section_id_9ce681e3-d3a4-4ebb-b164-b9082bb4ca3a">17.4</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92e8a0fa-a23a-4c49-a724-24fb0c2afcd4"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Skin Cancer Events </h2>
<p class="First">Patients should be told that exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor because of the increased risk for skin cancer [see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_3a472451-f208-4299-ac8d-4ac34fc23158">5.15</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46edf024-983e-4c9e-8a14-de12677d6fad"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Pregnancy Risks </h2>
<p class="First">Women of childbearing potential should be informed of the potential risks during pregnancy and told that they should use effective contraception prior to initiation of Rapamune therapy, during Rapamune therapy, and for 12 weeks after Rapamune therapy has been stopped [see <span class="Italics">Use in Specific Populations (<a href="#i4i_section_id_1c44ae4e-b680-4479-aacc-a8ee7f9a56d1">8.1</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ce681e3-d3a4-4ebb-b164-b9082bb4ca3a"></a><a name="section-16.4"></a><p></p>
<h2>17.4 FDA-Approved Patient Labeling </h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_d09a1f7d-62ea-41bf-b127-319aedbe4bf5"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PATIENT INSTRUCTIONS FOR RAPAMUNE (SIROLIMUS) ORAL SOLUTION</span></p>
<p> <span class="Bold">Bottles </span></p>
<a name="id_320c0818-4de4-4278-8fb3-87282afd4631"></a><table width="430.000">
<caption><span></span></caption>
<col align="left" width="30.7%">
<col align="left" width="69.3%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-02.jpg"></td>
<td align="left" valign="top"><p class="First">1. Open the solution bottle. Remove the safety cap by squeezing the tabs on the cap and twisting counterclockwise. </p></td>
</tr>
<tr>
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-03.jpg"></td>
<td align="left" valign="top"><p class="First">2. On first use, insert the adapter assembly (plastic tube with stopper) tightly into the bottle until it is even with the top of the bottle. Do not remove the adapter assembly from the bottle once inserted. </p></td>
</tr>
<tr>
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-04.jpg"></td>
<td align="left" valign="top"><p class="First">3. For each use, tightly insert one of the amber syringes with the plunger fully depressed into the opening in the adapter. </p></td>
</tr>
<tr>
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-05.jpg"></td>
<td align="left" valign="top"><p class="First">4. Withdraw the prescribed amount of Rapamune Oral Solution by gently pulling out the plunger of the syringe until the bottom of the black line of the plunger is even with the appropriate mark on the syringe. Always keep the bottle in an upright position. If bubbles form in the syringe, empty the syringe into the bottle and repeat the procedure. </p></td>
</tr>
<tr>
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-06.jpg"></td>
<td align="left" valign="top"><p class="First">5. You may have been instructed to carry your medication with you. If it is necessary to carry the filled syringe, place a cap securely on the syringe – the cap should snap into place. </p></td>
</tr>
<tr>
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-07.jpg"></td>
<td align="left" valign="top"><p class="First">6. Then place the capped syringe in the enclosed carrying case. Once in the syringe, the medication may be kept at room temperature or refrigerated and should be used within 24 hours. Extreme temperatures (below 36°F and above 86°F) should be avoided. Remember to keep this medication out of the reach of children. </p></td>
</tr>
<tr>
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-08.jpg"></td>
<td align="left" valign="top"><p class="First">7. Empty the syringe into a glass or plastic cup containing at least 2 ounces (1/4 cup, 60 mL) of water or orange juice, stir vigorously for one (1) minute and drink immediately. Refill the container with at least 4 ounces (1/2 cup, 120 mL) of water or orange juice, stir vigorously again and drink the rinse solution. Apple juice, grapefruit juice, or other liquids are NOT to be used. Only glass or plastic cups should be used to dilute Rapamune Oral Solution. The syringe and cap should be used once and then discarded. </p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><img alt="Icon" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-09.jpg"></td>
<td align="left" valign="top"><p class="First">8. Always store the bottles of medication in the refrigerator. When refrigerated, a slight haze may develop in the solution. The presence of a haze does not affect the quality of the product. If this happens, bring the Rapamune Oral Solution to room temperature and shake until the haze disappears. If it is necessary to wipe clean the mouth of the bottle before returning the product to the refrigerator, wipe with a dry cloth to avoid introducing water, or any other liquid, into the bottle. </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">US Pat. Nos</span>.: 5,100,899; 5,212,155; 5,308,847; 5,403,833; 5,536,729; 5,989,591. </p>
<p>This product's label may have been updated. For current package insert and further product information, please visit www.wyeth.com or call our medical communications department toll‑free at 1‑800‑934‑5556. </p>
<p>For Rapamune Oral Tablets: </p>
<p><span class="Bold">Wyeth</span><span class="Sup">®</span></p>
<p>Wyeth Pharmaceuticals Inc.<br>Philadelphia, PA 19101 </p>
<p>For Rapamune Oral Solution: </p>
<p><span class="Bold">Wyeth</span><span class="Sup">®</span></p>
<p>Manufactured for:<br>Wyeth Pharmaceuticals Inc.<br>Philadelphia, PA 19101 </p>
<p>MADE IN CANADA </p>
<p>W10431C034<br>ET01<br>Rev 07/08</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5e74cd5b-1b1b-4de7-9487-83f68735a274"></a><a name="section-18"></a><p></p>
<h1>Principal Dispaly Panel</h1>
<p class="First">Rapamune<span class="Sup">®</span></p>
<p>(sirolimus)</p>
<p>1 mg</p>
<p>1600 Tablets</p>
<div class="Figure"><img alt="Rapamune Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f&amp;name=0f26220a-f4ab-4ceb-9a98-a13dbdeed81f-10.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RAPAMUNE 		
					</strong><br><span class="contentTableReg">sirolimus tablet, sugar coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4227(NDC:0008-1041)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sirolimus</strong> (sirolimus) </td>
<td class="formItem">sirolimus</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>calcium sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>1-GLYCERYL MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALPHA-TOCOPHEROL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE (TRIANGLE) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RAPAMUNE;1;MG</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4227-8</td>
<td class="formItem">1600  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021110</td>
<td class="formItem">07/01/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0f26220a-f4ab-4ceb-9a98-a13dbdeed81f</div>
<div>Set id: 0f26220a-f4ab-4ceb-9a98-a13dbdeed81f</div>
<div>Version: 1</div>
<div>Effective Time: 20110429</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
